





Godina 2020. u kardiovaskularnoj medicini: zatajivanje srca i kardiomiopatije

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

 **Héctor Bueno**^{1,2,3,4*},
 **Brenda Moura**^{5,6},
 **Patrizio Lancellotti**^{7,8},
 **Johann Bauersachs**⁹

¹Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

²Cardiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital, Madrid, Spain

³Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain

⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

⁵Cardiology Department, Military Hospital, Porto, Portugal

⁶CINTESIS—Center for Health Technology and Services Research, Porto, Portugal

⁷Department of Cardiology, CHU Sart Tilman, University of Liège Hospital, GIGA Cardiovascular Sciences, Liège, Belgium

⁸Cardiology Departments, Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Bari, Italy

⁹Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

RECEIVED:
January 15, 2021

ACCEPTED:
January 16, 2021



CITATION: *Cardiol Croat.* 2021;16(3-4):140-56. | <https://doi.org/10.15836/ccar2021.140>

***ADDRESS FOR CORRESPONDENCE:** Héctor Bueno, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro, 3, Madrid 28029, Spain. / Phone: 34 914 531 200 - Ext 4110 / E-mail: hector.bueno@cnic.es

ORCID: Héctor Bueno, <https://orcid.org/0000-0003-0277-7596> • Brenda Moura, <https://orcid.org/0000-0001-6158-7368> Patrizio Lancellotti, <https://orcid.org/0000-0002-0804-8194> • Johann Bauersachs, <https://orcid.org/0000-0002-9341-117X>

TO CITE THIS ARTICLE: Bueno H, Moura B, Lancellotti P, Bauersachs J. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. *Cardiol Croat.* 2021;16(3-4):140-56. | <https://doi.org/10.15836/ccar2021.140>

TO LINK TO THIS ARTICLE: <https://doi.org/10.15836/ccar2021.140>

Reproduced from: Bueno H, Moura B, Lancellotti P, Bauersachs J. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. *Eur Heart J.* 2021 Feb 11;42(6):657-670. <https://doi.org/10.1093/eurheartj/ehaa1061>, by permission of Oxford University Press on behalf of the European Society of Cardiology.

© The Author(s) 2021.

All rights reserved, no part of this publication may be reproduced, stored in retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission of the Publishers.

For Permissions please email: journals.permissions@oup.com

The opinions expressed in the Journal item reproduced as this reprint are those of the authors and contributors, and do not necessarily reflect those of the European Society of Cardiology, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated.

The mention of trade names, commercial products or organizations, and the inclusion of advertisements in this reprint do not imply endorsement by the Journal, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings in the journal. The ultimate responsibility for the use and dosage of drugs mentioned in this reprint and in interpretation of published material lies with the medical practitioner, and the editors and publisher cannot accept liability for damages arising from any error or omissions in the Journal or in this reprint. Please inform the editors of any errors.

Oxford University Press, OPL, and European Society of Cardiology are not responsible or in any way liable for the accuracy of the translated reprint, for any errors, omissions, or inaccuracies, or for any consequences arising therefrom. Croatian Cardiac Society is solely responsible for the translation and this reprint.

Uvod

Prevalencija zatajivanja srca (HF) i dalje je visoka diljem svijeta, sa znatnim razlikama vezanima uz spol i regiju u učestalosti, liječenju i ishodom. U 2020. godini objavljeni su pozitivni pomaci uporabe biomarkera i slikovnih metoda za dijagnozu i prognozu dijastoličke disfunkcije, HF-a s očuvanom ejskijskom frakcijom ili monitoriranja kardiotsičnosti; objavljena je i nova definicija HF-a s oporavljenom ejskijskom frakcijom lijeve klijetke (LVEF). Dobrobiti od primjene inhibitora reninsko-angiotenzinsko-aldosteronskog sustava i beta-blokatora mogli bi se proširiti na bolesnike s LVEF-om do 55%. Sakubitri-valsartan je poboljšao remodelaciju lijeve klijetke, razinu biomarkera i stopu iznenadne srčane smrti.

Introduction

Heart failure (HF) prevalence remains high worldwide with significant sex-related and regional differences in its presentation, management, and outcomes. In 2020, advances in biomarkers and imaging techniques were reported for the diagnosis and prognosis of diastolic dysfunction, HF with preserved ejection fraction or monitoring cardiotoxicity; a new definition of HF with recovered left ventricular ejection fraction (LVEF) was released. Benefits of renin-angiotensin-aldosterone system inhibitors and β -blockers may extend to patients with an LVEF up to 55%. Sacubitril-valsartan improved LV remodelling, biomarker levels, and rates of sudden cardiac death. Two studies investigating the

Objavljene su dvije studije koje su istraživale učinke inhibitora natrij-glukoza kotransporter 2 empagliflozina i sotagliflozina u bolesnika s HF-om. Studija *EMPEROR-Reduced* u bolesnika s HF-om uz sniženu EF sa šećernom bolešću tipa 2 ili bez nje (T2DM) pokazala znatno smanjenje kardiovaskularnih (CV) smrti i učestalosti hospitalizacija zbog HF-a (HFH). U bolesnika s T2DM-om i HF-om uz spektar vrijednosti LVEF-a nakon aktualne hospitalizacije, studija *SOLOIST* pokazala je smanjenje primarnog zajedničkog ishoda (CV smrtnosti, ukupne HFH i hitnih pregleda zbog HF-a). Dodatno, u bubrežnih bolesnika, neovisno o prisutnosti šećerne bolesti (*DAPA-CKD*), dapagliflozin je prevenirao pogoršanje bubrežne funkcije. Dva novija lijeka, aktivator solubilne gvanilat ciklaze vericiguat i aktivator miozina omecamativ mekarbil, u velikim istraživanjima ishoda *VICTORIA* i *GALACTIC-HF* dominantno su smanjila HFH u visokorizičnih bolesnika s pogoršanjem HF-a. U studiji *AFFIRM-AHF* intravenska primjena željezove karboksimaltoze smanjila je HFH u bolesnika s manjkom željeza nakon dekompenzacije HF-a.

Godina 2020. bit će zapamćena kao godina bolesti uzrokovane koronavirusom (COVID-19). Pandemija uzrokovana teškim akutnim respiratornim sindromom koronavirusa 2 (SARS-CoV-2) imala je golem učinak na globalno zdravlje i ekonomiju. Kada ovaj članak bude objavljen, >80 milijuna osoba bit će zaraženo, a >1,75 milijuna ljudi će umrijeti od te bolesti. Velik će broj drugih osoba umrijeti ili će doći do pogoršanja njihovih bolesti, od kojih su u mnogih posrijedi CV bolesti, kao neizravan učinak straha izazvana traženja pomoći ili zbog kolapsa zdravstvenog sustava. Ipak, znanost i medicinska skrb nastavile su se razvijati tijekom godine. Ovaj članak daje osvrt na važne napretke u polju HF-a tijekom 2020. godine.

Epidemiologija

U svijetu živi više od 64 milijuna ljudi s HF-om, s procijenjenom prevalencijom od 1 do 2 % odraslih u razvijenim zemljama, najčešće uz nekoliko komorbiditeta.¹ Incidencija HF-a možda se globalno stabilizira, uz smanjenje broja u zemljama s visokim prihodima,² ali se povećava u zemljama s niskim prihodima, pomiče prema HF-u s očuvanom ejekcijskom frakcijom (HFpEF), te povećava zbog starenja populacije i porasta učestalosti pretilosti.¹ Životna dob, tradicionalni čimbenik rizika za HF, sjedilački stil života i socijalna deprivacija povezani su s pojavnošću HF-a.³ Zapravo, životni stil i socijalne odrednice zdravlja privlače sve više pažnju u epidemiologiji i skrbi bolesnika s HF-om.⁴ U bolesnika s novootkrivenom HF-om najčešći prvi sljedeći događaji jesu srčani incident (36 %), ponavljajuća HF (28 %) ili smrt (29 %).⁵

Netradicionalni čimbenik rizika, kao što je to implantacija elektrostimulatora srca, može imati ulogu u razvoju HF-a: unutar prvih dviju godina nakon implantacije u bolesnika bez poznatog HF-a, učestalost je fatalnog i nefatalnog HF-a 10,6 %, šest puta veća nego u za po dobi i spolu sparenih osoba bez HF-a i elektrostimulatora srca.⁶

Čini se da se učestalost smrtnosti od HF-a smanjuje sporije u općoj populaciji nego prethodnih godina.¹ Među bolesnicima s resinkronizacijskom terapijom (CRT) postupno smanjenje iznenadnih srčanih smrti prati se od 2000-ih godina⁷ s implikacijom uloge implantabilnih defibrilatora i koncepta sveobuhvatne HF skrbi.

Uočene su znatne regionalne razlike u zbrinjavanju akutnog HF-a, uključujući vrijeme i vrste primijenjenoga liječe-

sodium-glucose cotransporter 2 inhibitors empagliflozin and sotagliflozin in patients with HF were reported: the *EMPEROR-Reduced* trial in patients with HF with reduced EF with or without type 2 diabetes (T2DM) demonstrated a significant reduction in cardiovascular (CV) death and HF hospitalisations (HFH). In patients with T2DM and HF across the whole EF spectrum after a recent HFH, the *SOLOIST* trial showed a reduction in the primary endpoint of CV deaths, total HFH, and urgent visits for HF. In addition, in patients with kidney disease with or without diabetes mellitus (*DAPA-CKD*), dapagliflozin prevented the deterioration of renal function. Two novel drugs, the activator of soluble guanylate cyclase vericiguat and the myosin activator omecamtiv mecarbil, in the large outcome trials *VICTORIA* and *GALACTIC-HF* predominantly reduced HFH in high-risk patients with worsening HF. In the *AFFIRM-AHF* trial, intravenous ferric carboxymaltose reduced HFH in patients with iron deficiency after an HF decompensation.

Year 2020 will be remembered as the year of coronavirus disease of 2019 (COVID-19). The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a massive impact on global health and economy. When this article is published, >80 million people will have been infected and >1.75 million will have died of the disease. Many others will have died or worsened of their diseases, many with cardiovascular (CV) disease, as an indirect effect of the fear to seek assistance or the collapse of healthcare systems. Yet, advances in science and medical care continued developing during the year. This article reviews important advances in the field of heart failure (HF) presented in 2020.

Epidemiology

More than 64 million people are living with HF in the world, with an estimated prevalence of 1–2% among adults in developed countries, most often with several comorbidities.¹ The incidence of HF may be stabilizing globally, with decreases in higher-income countries,² but increases in lower-income countries, and a shift towards HF with preserved ejection fraction (HFpEF), and increasing due to population ageing and the increase in obesity.¹ Age, traditional risk factors for HF, a sedentary lifestyle, and social deprivation are associated with incident HF.³ Actually, lifestyle and social determinants of health are attracting more attention in the epidemiology and care of patients with HF.⁴ In patients with new-onset HF, the most common first events are cardiac events (36%), recurrent HF (28%), and death (29%).⁵

Non-traditional risk factors, such as pacemaker implantation may play a role in the development of HF: within the first 2 years after implantation in patients without known HF, the incidence of fatal and non-fatal HF is 10.6%, six times higher than for age- and gender-matched individuals without HF and pacemaker.⁶

Mortality rates of HF seem to be declining less rapidly than previously in the general population.¹ Among patients with cardiac resynchronization therapy (CRT), a gradual decrease in sudden cardiac death risk has been observed since the early 2000s⁷ with implications for the role of implantable defibrillators and the design of comprehensive HF care models.

Significant regional differences in the management of acute HF have been identified, including timing and types

nja,⁸ učestalosti i vremenskih trendova ponovnih prijema.^{2,9,10} Ipak, naglašena je važnost razlikovanja između pogoršanja kroničnog od novonastalog oblika HF-a u bolesnika u prvoj hospitalizaciji, jer bolesnici s pogoršanjem/kroničnim HF-om imaju mnogo veće opterećenje komorbiditetima i veći prilagođeni rizik mortaliteta i hospitalizacije zbog HF-a.^{10,11}

Klinička obilježja

DIJAGNOSTIKA I STRATIFIKACIJA RIZIKA

Slikovne metode

Slikovni prikaz ima vodeću ulogu u dijagnozi i stratifikaciji rizika u bolesnika s HF-om. Udruženje za zatajivanje srca Europskoga kardiološkog društva (HFA) u svojim je preporukama nedavno naglasilo središnju ulogu kompletnoga ehokardiografskog pregleda u bolesnika primljenog zbog akutnog zatajivanja srca (AHF).¹² Istraživana je dodatna vrijednost rutinske primjene magnetne rezonancije srca (CMR), kada se bolesnik stabilizira spram same ehokardiografije, kao pomoć pri dijagnozi uzroka HF koja nije povezana s ishemijskom bolešću srca.¹³ Selektivna primjena CMR-a, a ne rutinska, više je isplativa za utvrđivanje specifične etiologije HF-a. Važno je reći da bi CMR mogao koristiti pri boljem definiranju fenotipa HFpEF i izbora specifičnog liječenja, kao što bi antagonist mineralokortikoidnih receptora mogli biti za liječenje bolesnika s HFpEF-om i fibrozom miokarda.¹⁴⁻¹⁷ Dijagnoza HFpEF-a i dalje ostaje izazov, posebice u bolesnika s koegzistirajućim stanjima koja pridonose pojavi zaduhe. Dijastolička disfunkcija, uvećanje lijevog atrija, povećani tlak u lijevoj atriju i plućna hipertenzija uobičajeni su u takvih bolesnika.^{18,19} Algoritam procjene dijastoličke funkcije iz 2016. preporučeni od Europskog udruženja kardiovaskularnih slikovnih metoda (EACVI) pokazao je poboljšanu prognostičku vrijednost u usporedbi s onim iz 2009. godine.²⁰ Ipak, velik broj nejasno definiranih bolesnika čini kliničke odluke zahtjevnima.²¹ Analiza mehanike LA, naprezanja LA i globalnoga longitudinalnog naprezanja (GLS) lijeve klijetke (LV)²² omogućuje bolju klasifikaciju stupnja dijastoličke disfunkcije i poboljšava individualnu stratifikaciju rizika. Dva algoritma (*H2FPEF* i *ESC HFA-PEFF*) mogu olakšati postavljanje dijagnoze HFpEF-a. Ta dva izračuna imaju jednaku prediktivnu snagu za hospitalizaciju zbog HF-a i smrtni ishod među bolesnicima bez kliničke dijagnoze HF-a.²³ Iako je LVEF ključna za klasifikaciju HF-a, i dalje je riječ o gruboj metodi procjene funkcije LV-a. Intrigantno je da u 17 % bolesnika koji se inicijalno prikažu s očuvanom sistoličkom funkcijom LV-a pokaže kasnije smanjenje LVEF-a na <40 % u šestomjesečnom praćenju, što je povezano s više srčanih incidenata.²⁴ Parametri mehanizma LV-a (naprezanje LV-a, naprežanje slojeva i rad miokarda) poboljšavaju prognostičke podatke više od LVEF-a.^{22,25} Dobrobit liječenja (npr. sakubitril-valsartan, SV) na remodeliranje LV se bolje prikazuje *strainom* LV-a.²⁶ Mehanizam mehanike miokarda povezan je s disfunkcijom koronarne mikrovaskulature u bolesnika s hipertenzivnim HF-om.^{27,28} U AHF-u disfunkcija srčanog simpatikusa, što je ispitivano oslikavanjem s ¹²³I-jod-metajod-benzilguanidinom, povezana je s lošijim ishodima neovisno o vrijednostima LVEF-a.²⁹

Biomarkeri

Biomarkeri su ključni za dijagnozu i procjenu prognoze u bolesnika s HF-om. Cirkulirajući biomarkeri povezani uz

of treatments used,⁸ and rates and time trends of readmission.^{2,9,10} However, the importance of distinguishing worsening/chronic HF from new-onset HF in patients with first hospitalization has been highlighted, as patients with worsening/chronic HF have a significantly greater comorbidity burden and higher adjusted risks of mortality and HF readmission.^{10,11}

Clinical aspects

DIAGNOSTICS AND RISK STRATIFICATION

Imaging

Imaging is pivotal in the diagnosis and risk stratification of patients with HF. The European Society of Cardiology (ESC) Heart Failure Association (HFA) has recently highlighted in a position statement the central role of full echocardiographic examination in patients admitted for acute heart failure (AHF).¹² Once the patient is stabilized, the added value of routine cardiac magnetic resonance (CMR) over echocardiography alone to help diagnose the causes of HF not related to ischaemic heart disease has been questioned.¹³ Selective rather than routine CMR for identifying specific HF aetiologies is more cost effective. Noteworthy, CMR could serve to better define HFpEF phenotypes and to select patient specific therapies, such as MRA may be for HFpEF patients with myocardial fibrosis.¹⁴⁻¹⁷ The diagnosis of HFpEF remains challenging especially in patients with coexisting conditions that account for dyspnoea. Diastolic dysfunction, left atrial enlargement, elevated left atrial pressure, and pulmonary hypertension are common in these patients.^{18,19} The 2016 diastolic dysfunction grading algorithm proposed by the European Association of Cardiovascular Imaging has shown improved prognostic value compared to the 2009 one.²⁰ However, the high number of patients with doubtful classification renders clinical decision making challenging.²¹ The analysis of LA mechanics, LA strain, and left ventricular (LV) global longitudinal strain²² allows to better classify the degree of diastolic dysfunction and improves individual risk stratification. Two algorithms (*H₂FPEF* and *ESC HFA-PEFF*) may facilitate HFpEF diagnosis. These two scores have equivalent predictive power of incident HF hospitalization or death among patients without a clinical diagnosis of HF.²³ Although LV ejection fraction (LVEF) is key for HF classification, it remains a crude estimate of LV function. Intriguingly, 17% of patients with initially preserved LV systolic function show a decrease in LVEF below 40% at 6 months follow-up, which is associated with more cardiac events.²⁴ Parameters of LV mechanics (LV strain, multilayer strain and myocardial work) provide incremental prognostic information over LVEF.^{22,25} The benefit of treatment [i.e. sacubitril/valsartan (SV)] on LV remodelling is also better captured by LV strain.²⁶ Myocardial mechanics is linked to coronary microvascular dysfunction in patients with hypertensive HF.^{27,28} In AHF, cardiac sympathetic nerve dysfunction, as evaluated by ¹²³I-metaiodobenzylguanidine imaging, is associated with poor outcome irrespective of LVEF.²⁹

Biomarkers

Biomarkers are key for diagnosis and prognostic evaluation in patients with HF. Circulating biomarkers related to extracellular matrix regulation were abnormal in patients with HFpEF, displayed prognostic value, and were influenced favourably

regulaciju ekstracelularnog matriksa koji su povišeni u bolesnika s HFpEF-om, pokazali su prognostičku vrijednost te je primjena SV-a imala povoljan učinak na njih u studiji *PARAGON-HF*.³⁰ U HF-u sa sniženom LVEF (HFREF), apsolutne vrijednosti NT-proBNP, hsTnT i sST2 predviđale su ishode neovisno o dobi, spolu i kategoriji LVEF-a.³¹ Objavljene su razlike u razinama cirkulirajućih biomarkera vezano za starenje bolesnika s HF-om, uz povećanje razine proteina vezanih uz organizaciju ekstracelularnog matriksa, upalnih procesa, regulacije tumorskih stanica i slabije ekspresije funkcija tumorske proliferacije.³²

U AHF-u poseban je izazov utvrđivanje infekcije kao „okidača“. Procalcitonin (PCT) se pojavio kao alternativa CRP-u za potvrdu bakterijskih infekcija. U novim multicentričnim istraživanjima otvorenog dizajna, strategija PCT-om vođenim započinjanjem antibiotske terapije bila je efikasnija od standardne skrbi u poboljšanju kliničkih ishoda.³³ Omics fenotipizacija vjerojatna je sljedeća granica prema razumijevanju mehanizma bolesti i heterogenosti.³⁴ U nedavnom primjeru uključivanjem panela od triju biomarkera metabolita u procjenu rizika poboljšala se prognostička korist od NT-proBNP-a pri predviđanju dugoročne CV smrtnosti.³⁵

ZATAJIVANJE SRCA U VRIJEME PANDEMIJE COVID-A 19

Uloga receptora angiotenzin-kovertirajućeg enzima 2 (ACE) kod infekcije ljudskih stanica SARS-CoV-2 i u patofiziologiji COVID-a 19,³⁶ i loša prognoza kardioloških bolesnika s COVID-om 19³⁷ potaknuli su zabrinutost o potencijalnom štetnom učinku liječenja ACE inhibitorima i blokatorima angiotenzinskih receptora (ARB). Spomenuti lijekovi mogu ili smanjiti akutno oštećenje pluća preveniranjem angiotenzin-II posredovane upale pluća ili povećati SARS-CoV-2 plućno oštećenje up-regulacijom ACE2 receptora.^{38,39} Opservacijske studije odbacile su hipotezu o štetnom učinku ACEI/ARB-a.⁴⁰⁻⁴³ Studija *BRACE CORONA* nije utvrdila lošije ishode u bolesnika s COVID-om 19 randomiziranih u nastavak ili prekid njihova kroničnog liječenja ACEI/ARB-om (prikazana na ESC kongresu, još neobjavljeno). Učestalost AHF-a ili dekompenzacija kroničnog HF-a među bolesnicima s COVID-om 19 je visoka i s lošom prognozom.⁴⁴ U posredne učinke pandemije ubraja se smanjenje hospitalizacija zbog HF-a tijekom lokalnih izbijanja epidemije⁴⁵⁻⁴⁷ i porast bolničke smrtnosti,^{45,47} što je velik izazov za liječenje i praćenje bolesnika s HF-om te provođenje kliničkih istraživanja. Objavljene su preporuke za prevladavanje tih izazova.⁴⁸⁻⁵⁰

SPOL I ZATAJIVANJE SRCA

Žene čine polovicu bolesnika s HF-om. U njih je registrirana snižena učestalost HF-a do dobi od 75 godina i veći udio HFpEF-a, što je vjerojatno povezano s većom prevalencijom pretilosti i šećerne bolesti.¹ Žene s HF-om imaju više simptoma i lošiju kvalitetu života u usporedbi s muškarcima.⁵¹ Značajna razlika vezana za spol opisana je u Europi u liječenju akutnog i kroničnog HF-a^{8,52}, uključujući manju primjenu liječenja prema smjernicama – što je uglavnom objašnjeno starijom dobi i komorbiditetima više nego samim spolom – uz nižu stopu smrtnosti i hospitalizacija zbog HF-a u žena. Nepostojanje razlika vezanih uz spol za kliničke učinke terapije HF-a^{53,54} ne opravdava ove razlike, iako postoji mogućnost da žene s HF-om mogu imati dobit od liječenja do viših razina LVEF-a nego što se prije mislilo.⁵⁴ Drukčiji pogled na razliku prema

by SV in *PARAGON-HF*.³⁰ In HF with reduced LVEF (HFREF), absolute NT-proBNP, hs-TnT, and sST2 levels predict outcomes independent of age, sex, and LVEF category.³¹ Differential circulating levels of biomarkers associated with ageing in patients with HF have been reported, with increasing levels of proteins associated with extracellular matrix organization, inflammatory processes, and tumour cell regulation and lower expression of tumour proliferation functions.³²

In AHF, a specific challenge is to identify infection as a trigger of AHF. Procalcitonin (PCT) has emerged as an alternative for C-reactive protein in diagnosing bacterial infection. In a recent randomized, multicentre, open study, a strategy of PCT-guided initiation of antibiotic therapy was more effective than standard care in improving clinical outcomes.³³ Omics phenotyping is likely the next frontier to unravel disease mechanisms and heterogeneity.³⁴ As a recent example, incorporating a panel of three metabolite-based biomarkers into a risk score improved the prognostic utility of NT-proBNP by predicting long-term CV death.³⁵

HEART FAILURE DURING THE COVID-19 PANDEMIC

The role of the angiotensin-converting enzyme (ACE) receptor 2 in the infection of human cells by SARS-CoV-2 and in the pathophysiology of COVID-19,³⁶ and the poor prognosis of cardiac patients with COVID-19³⁷ raised the concern of a potential deleterious effect of the treatment with ACE inhibitors and angiotensin receptor blockers (ARB). These drugs may either decrease acute lung damage, prevent angiotensin-II-mediated pulmonary inflammation or increase the SARS-CoV-2 pulmonary damage by the up-regulation of ACE2 receptors.^{38,39} Observational studies refuted the hypothesis of a deleterious effect of ACEI/ARB.⁴⁰⁻⁴³ The *BRACE CORONA* trial found no worse outcomes in patients with COVID-19 allocated to continuation or interruption of their chronic ACEI/ARB treatment (presented at the ESC Congress, data not published). The incidence of AHF or decompensation of chronic HF among patients with Covid-19 is high and with poor prognosis.⁴⁴ Indirect effects of the pandemic included the reduction in HF hospitalizations during local outbreaks⁴⁵⁻⁴⁷ with increases in their hospital mortality,^{45,47} and major challenges for the management and Follow-up of HF patients, and the conduct of clinical trials. Recommendations to overcome these challenges have been released.⁴⁸⁻⁵⁰

SEX AND HEART FAILURE

Women account for half of patients with HF with a lower incidence rate until the age of 75 years, a higher proportion of HFpEF, probably related to the higher prevalence of obesity and diabetes mellitus.¹ Women with HF present a greater symptom burden and poorer quality of life as compared with men.⁵¹ Significant sex-related differences have been described in Europe in the management of acute and chronic HF^{8,52} including a lower use of guideline-directed medical therapies—which seem to be mostly explained by older age and comorbidity rather than by sex itself—with lower crude rates of death and HF hospitalization in women. The lack of sex-related differences in the clinical effect of HF therapies^{53,54} does not justify these differences, although the possibility has been suggested that women with HF might benefit from treatment to a higher level of LVEF than previously considered.⁵⁴ A different perspective of the gender gap

spolu kod HF-a jest manji udio ženskih autora u HF praktičnim smjernicama i studijama, u rasponu između 11 % i 24%, sa skromnim povećanjem tijekom vremena u referencama europskih i američkih smjernica, ali ne i u HF studijama. Važno je reći da su HF studije sa ženama prvim ili starijim autorima povezane s većim postotkom uključenih žena sudionica.⁵⁵

KOMORBIDITETI

Komorbidity su bitni jer utječu na kliničku sliku, liječenje i ishode bolesnika s HF-om. Opterećenje je komorbiditetima veće u starijih bolesnika, u žena i u onih s HFpEF-om⁵⁶⁻⁵⁸, što se često zanemaruje.⁵⁹ Posebice važna stanja u bolesnika s HF-om uključuju fibrilaciju atriya,⁶⁰ koja ima kompleksan odnos s HF-om i zahtijeva više istraživanja.^{61,62} Jedan takav primjer jest izostanak povećanja rizika od smrtnosti povezanog s porastom frekvencije srca u bolesnika s HFrEF-om i fibrilacijom atriya kad se uspoređuju sa sinusnim ritmom.^{60,63} Bubrežna je bolest još jedno takvo stanje, pri kojemu se bubrežna funkcija mijenja tijekom razvoja bolesti ili kao odgovor na liječenje HF-a. Klinički odgovori, uključujući pogoršanje bubrežne funkcije i pseudo-pogoršanje bubrežne funkcije, i njihovi patofiziološki kolerati, tj. funkcija tubula (odgovor na diuretike) povrhu procijenjene glomerularne filtracije (eGFR), trebaju se razumjeti kako bi bili pravilno liječeni, prilagođujući terapiju izmijenjenoj situaciji.^{64,65}

Specifične situacije

AKUTNO ZATAJIVANJE SRCA

U bolesnika s akutnim HFrEF-om, isaroxime, inhibitor sarkolemalne Na⁺/K⁺ pumpe aktivacijom SERCA2a pumpe, poboljšao je funkciju srca bez velikih nepovoljnih učinaka u maloj mehanicističkoj studiji.⁶⁶ Cimlanod, nitroxyl donor primijenjen infuzijom tijekom 48 sati, bio je bio prilično dobro podnošen u manjim dozama, dok su veće doze uzrokovale neprihvatljivu hipotenziju. Nastupilo je znatno poboljšanje vrijednosti NT-proBNP-a, ali ne i zaduhe (prikazano na HFA Discoveries, nije objavljeno). Niz preporuka stručnih društava rezimiralo je ulogu slikovnih metoda¹² ili liječenja AHF-a u specifičnim situacijama, kao što su akutni koronarni sindrom⁶⁷ ili fibrilacija atriya.⁶⁸

KARDIOGENI ŠOK

Istodobno, iako se čini da je incidencija kardiogenog šoka u padu, to stanje i dalje nosi veliki rizik od smrtnosti.⁶⁹ Ove su godine objavljeni nova klinička klasifikacija kardiogenog šoka⁷⁰ i dva mišljenja stručnih društava.^{71,72} Studija *SWedish evaluation of left Ventricular Assist Device* (SweVAD) istražiti će utjecaj mehaničke cirkulatorne potpore spram smjernica vođene medikamentne terapije na preživljavanje u bolesnika s AHF-om nepodobnih za transplantaciju srca.⁷³

PERIPARTALNA KARDIOMIOPATIJA

Peripartalna kardiomiopatija (PPCM) prvi je uzrok HF-a u žena za vrijeme / nakon trudnoće.⁷⁴⁻⁷⁶ U Registar ESC EORP uključeno je >700 žena s PPCM-om iz 49 zemalja. Pokazalo se da PPCM pogađa žene iz bilo koje regije ili etničke pripadnosti. Unutar 6 mjeseci nakon postavljanja dijagnoze prosječne učestalosti smrtnosti majke, ponovne hospitalizacije i neonatalne smrtnosti iznosila su 6 %, 10 % i 5 % uz registrirane značajne regionalne razlike. Do oporavaka LVEF-a došlo je kod 46 % žena.⁷⁷ Liječenje takvih bolesnica prikazano je u nedavno objavljenom članku.⁷⁸

in HF is the lower proportion of female authors in HF practice guidelines and trials, ranging between 11% and 24% only, with modest increases over time in European and US guidelines references but not in HF trials. Importantly, HF trials with a woman first or senior author are associated with a higher proportion of enrolled female participants.⁵⁵

COMORBIDITIES

Comorbidities are important because they impact the clinical presentation, management, and outcomes of HF patients. The burden of comorbidities is higher in older patients, women and those with HFpEF,⁵⁶⁻⁵⁸ which are often ignored.⁵⁹ Particularly relevant conditions in HF patients include atrial fibrillation,⁶⁰ which has complex interrelations with HF needing more research.^{61,62} One example is the lack of increase in mortality risk associated with elevated heart rate in patients with HFrEF and atrial fibrillation, as compared to sinus rhythm.^{60,63} Renal disease is one other, with renal function often changing during the course of the disease or as a response to HF therapies. Clinical responses, including worsening renal function and pseudo-worsening renal function, and their pathophysiological correlates, i.e. tubular function (diuretic response) beyond estimated glomerular filtration rate (eGFR), need to be understood to be properly managed, adapting therapies to the changing situation.^{64,65}

Specific situations

ACUTE HEART FAILURE

In patients with acute HFrEF, isaroxime, an inhibitor of the sarcolemmal Na⁺/K⁺ pump activating the SERCA2a pump, improved cardiac function without major adverse effects in a small mechanistic trial.⁶⁶ Cimlanod, a nitroxyl donor infused over 48 h, was reasonably well tolerated at a lower dose whereas higher doses caused unacceptable hypotension. There was improvement of NT-ProBNP but not on dyspnoea (presented at HFA Discoveries, data not published). A number of position papers have summarized the role of imaging¹² or the management of AHF in specific situations, such as acute coronary syndromes⁶⁷ or atrial fibrillation.⁶⁸

CARDIOGENIC SHOCK

While its incidence seems to be decreasing, cardiogenic shock still conveys a high mortality risk.⁶⁹ A new clinical classification,⁷⁰ and two position papers^{71,72} on cardiogenic shock have been published this year. The Swedish evaluation of left Ventricular Assist Device (SweVAD) will examine the impact of mechanical circulatory support vs. guideline-directed medical therapy on survival in a population of AHF patients ineligible for heart transplant.⁷³

PERIPARTUM CARDIOMYOPATHY

Peripartum cardiomyopathy (PPCM) is the first cause of HF in women during/after pregnancy.⁷⁴⁻⁷⁶ The ESC EORP registry on PPCM enrolled >700 women with this condition from 49 countries. It showed that PPCM affects women from any region or ethnicity. Within 6 months after diagnosis, the average rates of maternal mortality, readmission, and neonatal mortality were, respectively, 6%, 10%, and 5%, with marked regional variations. Recovery of LVEF occurred in 46% of women.⁷⁷ The management of these patients is reviewed in a recent paper.⁷⁸

ZATAJIVANJE SRCA S OPORAVLJENOM EJEKCIJSKOM FRAKCIJOM LIJEVE KLIJETKE

Ove je godine predložena radna definicija HF-a s oporavljenom ejekcijskom funkcijom lijeve klijetke (HFrecEF). Ona uključuje potvrdu smanjene (<40 %) LVEF na početku, apsolutno poboljšanje LVEF-a za >10 % i drugo mjerenje koje je pokazalo >40 %.⁷⁹ Obrat remodeliranja LV-a povezan je s poboljšanom kontraktilnošću miocita i šupljine LV-a te boljim kliničkim ishodima. Međutim, u znatnog se udjela bolesnika s HFrecEF-om ponovno razvije disfunkcija LV-a i HF-a. Usprkos oporavku strukturnih i funkcionalnih oštećenja, mnoge molekularne promjene koje su nastale na više razina tijekom LV remodeliranja ostaju disregulirane. Stoga se smjernicama vođena medikamentna terapija i terapija uređajima za bolesnike s HFrecEF-om treba nastaviti neodređeno uz učestalo kliničko praćenje.⁷⁹

ZATAJIVANJE SRCA U BOLESNIKA S KARCINOMOM

Uloga CV slikovnih metoda u bolesnika s karcinomom koji primaju kardiotoksičnu terapiju istaknuta je u preporukama HFA¹² i smjernicama Europskog društva za medicinsku onkologiju.⁸⁰ Uloga fokusne ehokardiografije⁸¹ i CMR-a⁸² također je bila nedavno publicirana. U svakodnevnoj je praksi potrebno biti pažljiv pri uporabi metode kasnog nakupljanja gadolinija ili kvalitativnog T2 slikovnog STIR prikaza za isključenje miokarditisa izazvanog *checkpoint* inhibitorima.⁸³ Slikovne su metode temelj praćenja kardiotoksičnosti i utvrđivanja suptilnih pogoršanja funkcija miokarda koje se pojavljuju prije prelaska tradicionalnog praga sistoličke disfunkcije LV-a (LVEF <50 %).^{84,85}

DISFUNKCIJA DESNE KLIJETKE

Disfunkcija desne klijetke (RV) i desnog atrija pridonosi HFpEF-u. Isto tako, disfunkcija RV-a (smanjena sistolička brzina RV-a i promjena njegove frakcijske areje) i oštećenje sprege RV – plućna arterija češće se utvrde u bolesnika s HFpEF-om u kojih se pri naporu razvija plućna kongestija.⁸⁶ Aktivacija endotelin i adrenomedulin neurohormonalnih puteva povezana je s plućnim hemodinamskim poremećajima, smanjenom frakcijskom rezervom RV-a, smanjenim udarnim volumenom srca i većim smanjenjem vršnog VO₂ u bolesnika s HFpEF-om.⁸⁷ Najčešći uzroci disfunkcije desne klijetke (RVD) jesu bolesti lijeve strane srca (46 %), plućna tromboembolijska bolest (18 %), kronična plućna bolest/hipoksija (17 %) i plućna arterijska hipertenzija (11 %). Prosječna je jednogodišnja smrtnost u bolesnika s RVD-om je velika (>40 %), najveća među bolesnicima s kroničnom plućnom bolesti.⁸⁸ Prisutnost RVD-a i implantacija CRT-a predviđaju pogoršanje remodelinga LV-a i preživljenja.⁸⁹

Farmakoterapija

ANGIOTENZIN RECEPTOR-NEPRILISIN INHIBITORI (STUDIJE PARAGON, PARADIGM, PARALLAX)

Angiotenzin receptor-neprilisin inhibitori (ARNI) u subanalizi studije *PARADIGM-HF* pokazuje smanjenje rizika od iznenadne srčane smrti, neovisno o uporabi implantabilnih srčanih defibrilatora.⁹⁰ Smanjenje volumena klijetki i povećanje LVEF-a nađeno je pri standardnoj ehokardiografiji u bolesnika

HF WITH RECOVERED LEFT VENTRICULAR EJECTION FRACTION

This year, a working definition of HF with recovered left ventricular ejection fraction (HFrecEF) has been proposed. This includes: (i) documentation of a decreased LVEF < 40% at baseline; (ii) ≥10% absolute improvement in LVEF; and (iii) a second measurement of LVEF >40%.⁷⁹ Reverse LV remodelling is associated with improved myocyte and LV chamber contractility and better clinical outcomes. However, a significant proportion of patients with HFrecEF develop recurrences of LV dysfunction and HF. Despite improvements in structural and functional abnormalities, many of the multilevel molecular changes occurring during LV remodelling remain dysregulated in reverse remodelled hearts. Therefore, guideline-directed medical and device therapy for patients with HFrecEF should be continued indefinitely with close clinical follow-up.⁷⁹

HF IN CANCER PATIENTS

The role of CV imaging in cancer patients receiving cardiotoxic therapies has been highlighted in a position statement by the HFA¹² and in the European Society for Medical Oncology guidelines.⁸⁰ The role of focus echocardiography⁸¹ and CMR⁸² has also been recently discussed. In daily practice, caution should, however, be given if using late gadolinium enhancement or qualitative T2-weighted STIR imaging-only approach for the exclusion of checkpoint inhibitor-associated myocarditis.⁸³ Imaging is cornerstone for monitoring cardiotoxicity and identifying subtle impairment of myocardial function occurring prior crossing the traditionally defined threshold of LV systolic dysfunction (LVEF < 50%).^{84,85}

RIGHT VENTRICULAR DYSFUNCTION (RVD)

RV and right atrium dysfunction contribute to HFpEF pathophysiology. Also, RV dysfunction (lower RV systolic velocity and RV fractional area change) and impairment in RV-pulmonary artery coupling are more frequently found in HFpEF patients developing acute lung congestion with exercise.⁸⁶ Activation of the endothelin and adrenomedullin neurohormonal pathways is associated with pulmonary haemodynamic derangements, reduced RV functional reserve, reduced cardiac output, and more severe impairment of peak VO₂ in HFpEF patients.⁸⁷ The most common causes of RVD are left-sided heart diseases (46%), pulmonary thromboembolic disease (18%), chronic lung disease/hypoxia (17%), and pulmonary arterial hypertension (11%). Average 1-year mortality in patients with RVD is high (>40%), highest among chronic lung disease patients.⁸⁸ The presence of RVD at CRT implantation predicts worsening LV remodelling and survival.⁸⁹

Pharmacotherapies

ANGIOTENSIN RECEPTOR-NEPRILISIN INHIBITORS (PARAGON, PARADIGM, PARALLAX)

Angiotensin receptor-neprilysin inhibitor (ARNI) showed, in a sub-analysis of *PARADIGM-HF*, a reduction in sudden cardiac death risk regardless of the use of implantable cardiac defibrillators.⁹⁰ Reduction in ventricular volumes and increase in LVEF have been observed with standard echocardiography in patients after 6 months on SV, but improvement in global longitudinal strain is apparent after 3 months.²⁶ In

nakon 6 mjeseci liječenja primjenom SV-a, dok se poboljšanje longitudinalnog naprezanja pojavljuje nakon 3 mjeseca.²⁶ U maloj skupini bolesnika u terminalnoj fazi bubrežne bolesti primjena SV-a pokazala se učinkovitom i sigurnom.⁹¹ Istraživanje *LIFE* u kojemu se uspoređuje SV s valsartanom u NYHA IV. stadiju bolesnika s HFrEF-om, premda je prije vremena prekinuta zbog pandemije COVID-a 19, donosi informacije o liječenju ARNI-jem u bolesnika s uznapredovalim HF-om.⁹²

Istraživanje *PARALLAX* testiralo je učinkovitost SV-a u usporedbi s optimalnom temeljnom terapijom u bolesnika s HFpEF-om. Utvrđeno je snižavanje vrijednosti NT-proBNP-a (do 12 tjedana od početne vrijednosti), no nije bilo učinka na 6-minutnu hodnu prugu (do 24 tjedna od početnog testiranja); spomenut je prikazan na kongresu ESC 2020. – podaci nisu publicirani. U studiji *PARAGON* u bolesnika s HFpEF-om primjena SV-a nije rezultirala nižom učestalošću hospitalizacija zbog HF-a i smrću. Od 12 prespecificiranih subgroupnih analiza, čini se da spol i LVEF modificiraju učinak SV-a spram valsartana, u usporedbi s primarnim zajedničkim ishodom. Premda nije uočen pozitivan ishod u muškaraca, nađeno je znatno smanjenje hospitalizacija u žena.⁹³ Isto tako, čini se da bolesnici imaju više dobrobiti od SV-a ako se s liječenjem započine ranije tijekom hospitalizacije.⁹⁴ Temeljni i srednji sistolički tlak od 120 do 129 mmHg identificiran je kao najmanje rizičan u bolesnika s HFpEF-om, no djelovanje SV-a na smanjenje tlaka ne utječe na njegov konačni učinak na ishod, neovisno o spolu.⁹⁵ U usporedbi s valsartanom, SV smanjuje rizik od učinaka na bubrege i usporuje pad u stupnju procijenjene glomerularne filtracije.⁹⁶ Smanjenje razine mokraćne kiseline također je povezano s poboljšanim ishodom.⁹⁷ Metaanaliza učinkovitosti različitih antagonista RAAS-a u kliničkim istraživanjima koja su provedena na bolesnicima s HFpEF-om (*PEP-CHF*, *CHARM-preserved*, *I-PRESERVE*, *TOPCAT*, *PARAGON-HF*) pokazuje da nema statistički značajne razlike u ukupnom ili CV mortalitetu pri liječenju antagonistima RAAS-a i placebo, no utvrđeno je signifikantno smanjenje rizika od hospitalizacija zbog HF-a u skupini liječenoj ARNI-jem, u usporedbi s kontrolnom skupinom (OR, 0,73; 95% CI, 0,61 – 0,87) i skupinom bolesnika na ARB (OR, 0,80; 95% CI, 0,71 – 0,91).⁹⁸

Analiza podataka bolesnika iz studija *PARADIGM-HF* i *PARAGON-HF* (SV prema enalaprilu kod HFrEF-a te SV prema valsartanu kod HFpEF-a), kao i studije *CHARM-Alternativa* i *CHARM-Preserved* (kandesartan prema placebo) pokazuje da primjena SV-a u usporedbi s inhibitorima RAAS-a poboljšava ishode kroz različite razine LVEF-a, uz smanjenje rizika (RR) od 0,54 (95% CI, 0,45 – 0,65) za ponavljani zajednički ciljni ishod u usporedbi s placebo (P<0,001). Povoljni ishodi liječenja bili su značajni u bolesnika s LVEF-om <60%, ali ne i u onih s LVEF-om >60%.⁹⁹ Rezultati su bili usporedivi s prethodnom *post hoc* analizom iz studije *TOPCAT* i studija s beta-blokatorima, što pokazuje da je granična razina LVEF-a za povoljni ishod liječenja bila oko 55%. Analize pokazuju da u studijskoj populaciji s LVEF-om od 40 do 55% mogu biti uspješni različiti načini liječenja HF-a (slika 1).¹⁰⁰

NATRIJ-GLUKOZA KOTRANSPORTER 2 INHIBITORI (ISTRAŽIVANJA *EMPEROR-REDUCED*, *DAPA-HF*, *SOLOIST*, *VERTIS*, *SUGAR-DM-HF*, *EMPA-TROPISM [ATRU-4]*)

U bolesnika s dijabetesom tipa 2 empagliflozin i dapagliflozin, lijekovi iz skupine natrij-glukoza kotransporter 2 (SGLT-2)

a small cohort of patients with end stage renal disease, SV showed efficacy and safety.⁹¹ The *LIFE* Trial, comparing SV to valsartan in NYHA Class IV HFREF patients, although prematurely interrupted because of the COVID 19 pandemia, will still provide information about ARNI as a treatment option for advanced HF patients.⁹²

The *PARALLAX* trial tested the efficacy of SV vs. optimal individualised background therapy in HFpEF patients and found a reduction in NT-proBNP from baseline to 12 weeks but no effect on six-minute walk distance from baseline to 24 weeks (presented at ESC 2020—data not published). In the *PARAGON* Trial in patients with HFpEF, SV did not result in a lower rate of total hospitalizations for HF and death. Of the 12 pre-specified subgroup analyses, sex and LVEF appeared to modify the effect of SV vs. valsartan on the primary composite outcome. Although no benefit was apparent in men, there was a significant reduction in HF hospitalizations in women.⁹³ Also, patients seemed to derive more benefit from SV when started early after hospitalization.⁹⁴ Baseline and mean achieved systolic blood pressure of 120–129 mm Hg identified the lowest risk HFpEF patients, but the blood pressure-lowering effects of SV did not account for its effects on outcomes, regardless of sex.⁹⁵ Compared with valsartan, SV reduced the risk of renal events and slowed the decline in estimated glomerular filtration rate.⁹⁶ Reduction in serum uric acid was also associated with improved outcomes.⁹⁷ A meta-analysis assessing the efficacy of different renin-angiotensin-aldosterone system (RAAS) antagonists in clinical trials performed in HFpEF patients (*PEP-CHF*, *CHARM-preserved*, *I-PRESERVE*, *TOPCAT*, *PARAGON-HF*) showed no statistical difference in all-cause and CV mortality among RAAS antagonists and placebo, but a significantly decreased risk in HF hospitalizations in patients allocated to receive ARNI compared with controls (OR, 0.73, 95% CI, 0.61–0.87) and ARB (OR 0.80, 95% CI, 0.71–0.91).⁹⁸

A patient-level data analysis from the *PARADIGM-HF* and *PARAGON-HF* trials (SV vs. enalapril in HFrEF and SV vs. valsartan in HFpEF, respectively), and the *CHARM-Alternativa* and *CHARM-Preserved* trials (candesartan vs. placebo) showed that, compared with RAAS inhibitors, SV improved outcomes across the range of LVEF, with a risk reduction (RR) of 0.54 [95% confidence interval (CI) 0.45–0.65] for the recurrent primary endpoint compared with putative placebo (P<0.001). Treatment benefits were robust in patients with LVEF < 60%, but not in those with LVEF > 60%.⁹⁹ These results are in line with prior *post hoc* analyses from the *TOPCAT* study and β -blocker trials suggesting that the cut-off of LVEF for a beneficial treatment effects is 55%. These analyses show that in the sparsely studied population of patients with an LVEF of 40–55%, several HF treatments might provide benefit (Figure 1).¹⁰⁰

SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (*EMPEROR-REDUCED*, *DAPA-HF*, *SOLOIST*, *VERTIS*, *SUGAR-DM-HF*, *EMPA-TROPISM [ATRU-4]*)

In patients with type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitors empagliflozin and dapagliflozin reduce the risk of HF hospitalization regardless of baseline CV risk or history of HF.^{101,102} In The *VERTIS* trial, ertugliflozin did neither significantly reduce CV events, nor the combined




FIGURE 1. Results from different trials testing a number of drugs commonly used to treat heart failure, pointing to an extended benefit up to a left ventricular ejection fraction of 55%. For patients with left ventricular ejection fraction >55%, a population group usually presenting several comorbidities, there is still no evidence of a drug improving prognosis. Reprinted from Böhm et al.¹⁰⁸

(from Bueno H, Moura B, Lancellotti P, Bauersachs J. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. *Eur Heart J.* 2021 Feb 11;42(6):657-670. <https://doi.org/10.1093/eurheartj/ehaa1061>, by permission of OUP on behalf of the ESC)

inhibitora, smanjuju rizik od hospitalizacija zbog HF-a neovisno o početnom CV riziku ili anamnestičkim podacima o HF-u.^{101,102} U studiji *VERITAS* primjena ertugliflozina nije znatno smanjila CV događaje ni zajednički ishod (CV smrtnost i hospitalizacije zbog HF-a)¹⁰³, no smanjena je učestalost hospitalizacija zbog HF-a.¹⁰⁴

Studija *DAPA-HF* u bolesnika s HFrEF-om je pokazala signifikantno smanjenje CV smrtnosti i događaja vezanih za HF.^{105,106} Ovaj značajni učinak bio je analiziran u nekoliko istraživanja koja su objavljena tijekom 2020. Povoljno djelovanje dapagliflozina nije ovisilo o tome ima li bolesnik dijabetes ili nema, a pojavljivalo se pri svim vrijednostima HbA1C¹⁰⁷, kao i neovisno o temeljnoj bubrežnoj funkciji, arterijskom tlaku, životnoj dobi ili terapiji HF-a.¹⁰⁸⁻¹¹¹ Dapagliflozin poboljšava simptome, tjelesnu kondiciju i kvalitetu života¹¹² i pokazuje da je troškovno učinkovit u liječenju HFrEF-a u zdravstvenim sustavima Velike Britanije, Njemačke i Španjolske.¹¹³ Dapagliflozin također snizuje stupanj sniženja bubrežne funkcije u bolesnika s HFrEF-om¹¹¹, kao i u onih s kroničnom bubrežnom bolesti (CKD), u skladu s rezultatima studije *DAPA-CKD* u kojoj je također uočeno da liječenje tim lijekom smanjuje rizik od pogoršanja renalne funkcije, terminalnoga stadija bubrežne bolesti ili smrtnog ishoda.¹¹¹ Protektivni je učinak registriran u bolesnika neovisno o prisutnosti dijabetesa.^{111,114}

endpoint of CV death/HF hospitalization¹⁰³ but reduced HF hospitalizations.¹⁰⁴

In patients with HFrEF, *DAPA-HF* has demonstrated a significant reduction in CV mortality and HF events.^{105,106} This robust effect was analysed in more detail in several seminal papers published in 2020. The benefit of dapagliflozin was independent of the diabetes status, occurring across all levels of HbA1C,¹⁰⁷ as well as of baseline renal function or blood pressure, patient age, or background HF therapy.¹⁰⁸⁻¹¹¹ Dapagliflozin improved symptoms, physical function, and quality of life¹¹² and was shown to be a cost-effective treatment for HFrEF in the UK, German, and Spanish healthcare systems.¹¹³ Dapagliflozin also reduces the rate of decline in renal function in HFrEF patients,¹¹¹ as well as in patients with chronic kidney disease, as shown in the *DAPA-CKD* trial, where treatment with dapagliflozin reduced the risk of worsening renal function, end-stage kidney disease, or death.¹¹¹ This protective effect was observed in patients with or without diabetes.^{111,114}

Empagliflozin also showed marked beneficial effects in HFrEF patients independently from diabetes status, with a significant reduction in the primary composite endpoint of CV death and HF events (hazard ratio (HR), 0.75; 95% CI, 0.65–

Empagliflozin također pokazuje značajan povoljni učinak u bolesnika s HFrEF-om neovisno o dijabetesu, sa znatnim smanjenjem u primarnome zajedničkom ishodu od CV smrtnosti i događaja vezanih s HF-om (*hazard ratio* – HR, 0,75; 95 % CI, 0,65 – 0,86; $P < 0,001$), sekundarnom ishodu – ukupnim hospitalizacijama zbog HFa (HR, 0,70; 95 % CI, 0,58 – 0,85; $P < 0,001$), godišnjem padu u eGFR (–0,55 vs. –2,28 mL/min/1,73 m² od površine tijela po godini; $P < 0,001$), riziku od ozbiljnih renalnih ishoda¹¹⁵, riziku i ukupnom broju bolničkih i ambulantnih pogoršanja HF-a, što je registrirano rano nakon početka liječenja i održava se trajanjem liječenja.¹¹⁶ Povoljni se učinak također bilježi u manjem opsegu i u bolesnika koji su već prije liječeni ARNI-jem¹¹⁷, neovisno o prisutnosti dijabetesa i vrijednostima HbA1c,¹¹⁸ u onih s kroničnom bolešću bubrega i bez nje i neovisno o težini temeljnog oštećenja bubrega.¹¹⁹

U studiji *SUGAR-DM-HF* empagliflozin snizuje volumene lijeve klijetke mjereno magnetnom rezonancijom u bolesnika s HFrEF-om i tipom 2 dijabetesa ili preddijabetesa.¹²⁰ Mehanistička studija *EMPA-TROPISM (ATRU-4)* pokazuje povoljan učinak empagliflozina u poboljšanju volumena i mase lijeve klijetke, sistoličke funkcije lijeve klijetke, funkcionalnog kapaciteta i kvalitete života, u bolesnika s HFrEF-om bez dijabetesa.¹²¹ Ako se zbroje svi dokazi, može se utvrditi da SGLT-2 inhibitori snizuju ukupnu i CV smrtnost, poboljšavaju bubrežnu funkciju u bolesnika s HFrEF-om, podržavajući ulogu dapagliflozina i empagliflozina u smislu standardne skrbi za bolesnike s HFrEF-om.^{119,122}

Sotagliflozin je SGLT-2 inhibitor koji također pokazuje gastrointestinalnu SGLT-1 inhibiciju i time smanjuje intestinalnu apsorpciju glukoze. Proučavan je u bolesnika s tipom 2 dijabetesa nakon nedavne hospitalizacije zbog pogoršanja HF-a (*SOLOIST-WHF*). Bolesnici su uključeni neovisno o LVEF-u, a 78 % njih imalo je LVEF <50 %. Primarni zajednički cilj (CV smrtnost, ukupni broj hospitalizacija i hitan pregled zbog HF-a) bio je značajno snižen u onih liječenih sotagliflozinom (HR, 0,67; 95 % CI, 0,52 – 0,85; $P < 0,001$). Rezultati su konzistentni među subgrupama, a posebno u osoba s LVEF-om >50 %.¹²³ Sotagliflozin je također proučavan u bolesnika s tipom 2 dijabetesa, kroničnom bolešću bubrega i povećanim CV rizikom (*SCORED*).¹²⁴ Primarni zajednički ishod (CV smrtnost, ukupne hospitalizacije i hitni pregledi zbog HF-a) bio je znatno snižen u onih liječenih sotagliflozinom (HR, 0,67; 95 % CI, 0,52 – 0,85; $P < 0,001$). Nužno je napomenuti da su obje studije sa sotagliflozinom prekinute ranije nego što je bilo planirano zbog prekida financiranja od sponzora.

AKTIVATOR SOLUBILNE GUANILAT CIKLAZE (STUDIJE VICTORIA, VITALITY, CAPACITY)

Aktivator solubilne guanilat ciklaze (sGC) vericiguat istraživan je u studiji *VICTORIA* na 5050 bolesnika s nedavnom dekompenziranom fazom kroničnog HF i LVEF <45%.^{125,126} Vericiguat znatno smanjuje primarni ishod od CV smrti ili prve hospitalizacije zbog HF-a (HR, 0,90; 95 % CI, 0,82 – 0,98; $P = 0,002$). Dok vericiguat značajno smanjuje hospitalizacije zbog HF-a (HR, 0,90; 95 % CI, 0,81 – 1,00), CV smrtnost se nije znatnije smanjila. Nepoželjni su događaji slični kod skupine na vericiguatu i placebo. Nadalje, proučavana je usporedba omjera rizika i apsolutnoga relativnog rizika u trima velikim nedavno objavljenim studijama s bolesnicima u HFrEF-u. Analiza omjera rizika pokazuje manji učinak liječenja u studiji *VICTORIA* nego u *DAPA-HF* i *PARADIGM-HF*, dok usporedba događaja tijekom 12 mjeseci za primarni ishod naglašava

0,86; $P < 0,001$), the secondary endpoints of total HF hospitalizations (HR, 0,70; 95% CI, 0,58–0,85; $P < 0,001$), the annual rate of decline in the estimated glomerular filtration rate (–0,55 vs. –2,28 mL/min/1,73 m² of body-surface area per year, $P < 0,001$), the risk of serious renal outcomes,¹¹⁵ and the risk and total number of inpatient and outpatient worsening HF events, which starts early after the initiation of treatment and remains during the duration of treatment.¹¹⁶ These beneficial effects were also observed to a similar extent in patients pre-treated with ARNI¹¹⁷ and were independent of baseline diabetes status and across the continuum of HbA1c,¹¹⁸ and in patients with and without CKD and regardless of the severity of kidney impairment at baseline.¹¹⁹

In the *SUGAR-DM-HF* study, empagliflozin reduced LV volumes measured by CV magnetic resonance in patients with HFrEF and type 2 diabetes or prediabetes.¹²⁰ The mechanistic trial *EMPA-TROPISM (ATRU-4)* showed the beneficial effect of empagliflozin in improving LV volumes, LV mass, LV systolic function, functional capacity, and quality of life in non-diabetic patients with HFrEF¹²¹ (ref). Taken together, SGLT-2 inhibitors reduce all-cause and CV mortality and improve renal outcomes in patients with HFrEF, supporting the role of dapagliflozin and empagliflozin as a new standard of care for patients with HFrEF.^{119,122}

Sotagliflozin, another SGLT-2 inhibitor that displays also gastrointestinal SGLT-1 inhibition and thus reduces intestinal glucose absorption, was investigated in patients with type 2 diabetes after a recent hospitalization for worsening heart failure (*SOLOIST-WHF*). Patients were included independent of their ejection fraction, and 78% of patients had an ejection fraction <50%. The primary endpoint of CV death, total hospitalizations, and urgent visits for HF was significantly reduced in patients treated with sotagliflozin (HR, 0,67; 95% CI, 0,52–0,85; $P < 0,001$). The results were consistent among subgroups and especially also in patients with an EF >50%.¹²³ Sotagliflozin was also investigated in patients with type 2 diabetes, chronic kidney disease, and elevated CV risk (*SCORED*);¹²⁴ primary endpoint (changed during the study to a composite of CV death, total HF hospitalizations and urgent visits for HF) was significantly reduced in patients treated with sotagliflozin (HR, 0,67; 95% CI, 0,52–0,85; $P < 0,001$). It has to be mentioned that both sotagliflozin trials had to be stopped earlier than planned because of loss of funding from the sponsor.

ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (VICTORIA, VITALITY, CAPACITY)

The activator of soluble guanylate cyclase (sGC) vericiguat was investigated in the *VICTORIA* study in 5050 patients with recently decompensated chronic HF and LVEF < 45%.^{125,126} Vericiguat significantly reduced the primary outcome of CV death or first HF hospitalisation (HR, 0,90; 95% CI, 0,82–0,98; $P = 0,02$). While vericiguat significantly reduced HF hospitalisations (HR, 0,90; 95% CI, 0,81–1,00), CV deaths were not significantly diminished. Adverse events were largely similar among the vericiguat and placebo groups. An analysis comparing HRs and absolute RR in three large recent HFrEF trials demonstrated that while the HR suggests a smaller treatment effect in *VICTORIA* than in the *DAPA-HF* and *PARADIGM-HF* trials, a comparison of 12-month event rates for the primary outcome pointed to a comparable benefit

usporedivu korist tijekom svih triju studija.^{127,128} Postoji značajna interakcija učinaka vericiguata prema bazalnim vrijednostima NTproBNP-a. *Post hoc* analiza pokazuje povezanost dobrobita vericiguata u smislu primarnog ishoda u bolesnika sa vrijednostima NT-proBNP-a do 8000 pg/mL, uz najveću dobrobit u onih s vrijednostima NTproBNP-a <4000 pg/mL (HR, 0,77, 95 % CI, 0,68 – 0,88).¹²⁹

Vericiguat se proučavao u bolesnika s HFpEF-om u studiji *VITALITY*.¹²⁸ Nađeno je da nema povoljnog učinka na kvalitetu života i podnošenje napora.¹³⁰ Slično tomu, u studiji *CAPACITY* praliciguat lijek iz skupine sGC stimulatora dobro se tolerirao, no nije bilo utjecaja na primarni cilj – učinak na vršnu potrošnju kisika (pVO₂), niti druge predefinirane ishode.¹³¹

AKTIVATORI I INHIBITORI MIOZINA

Omecantiv mecarbil (studije *GALACTIC-HF*, *EXPLOER-HCM*)

Aktivator srčanog miozina *omecantiv mecarbil*, koji mijenja kardiomiocitnu kontrakciju, daje se dvaput na dan na temelju vrijednosti lijeka u plazmi, značajno smanjuje primarni cilj (hospitalizacije poradi HF i CV smrtnost) u bolesnika sa HFrEF i nedavnim događajem vezanim za HF (HR, 0,92; 95% CI, 0,86–0,99; P = 0,03), no nema utjecaj na bilo koji sekundarni cilj (CV smrtnost, promjene u stupnjevanju simptoma, prva hospitalizacija zbog HF-a, ukupna smrtnost).¹³²

Sličan lijek, *danicamtiv*, povećava udarni volumen, povećava globalno longitudinalno i circumferencijalno naprezanje, smanjuje minimalni volumni indeks LA, a povećava funkcijski indeks LA kada se uspoređuje s placebom u manjoj kliničkoj studiji 2a faze na 40 bolesnika sa stabilnom HFrEF.¹³³ S druge strane, *mavacamten*, miozin inhibitor, znatno poboljšava kombinirani primarni cilj, parametar povećanja vršne potrošnje kisika uz snižavanje NYHA stadija, u fazi 3 kliničke studije, u bolesnika s opstruktivnom hipertrofičnom kardiomiopatijom. Također se poboljšava nalaz opstrukcije izlaznoga trakta LV-a, kao i klinički nalaz.¹³⁴

Ostala terapija

ŽELJEZNA KARBOKSIMALTOZA (STUDIJA *AFFIRM-AHF*)

U bolesnika s nedostatkom željeza, hospitaliziranih zbog akutnog HF-a (*AFFIRM-AHF*)¹³⁵, intravenska primjena željezne karboksimaltoze u usporedbi s placebom, povezana je sa snižavanjem ukupnoga broja hospitalizacija zbog HF-a i CV smrtnosti (RR 0,79, 95 % CI 0,62 – 1,01, P = 0,059). U prespecificiranoj analizi, u vremenu pandemije COVID-a 19, nađena je statistički značajna razlika u korist željezne karboksimaltoze za primarni cilj, ali ne i u smrtnosti zbog rizika od CV smrtnosti.¹³⁶

MIRCORNA-132 INHIBICIJA

U prvome kliničkom pokusu ograničenom na malom broju bolesnika s HF-om, lijek CDR132L antisence oligonucleide, usmjeren izravno protiv miR-132,¹³⁷ dobro se tolerirao uz poboljšanje funkcije srca.¹³⁸

CJELOKUPNA FARMAKOLOŠKA TERAPIJA KOJA PREINAČUJE TIJEK BOLESTI

Koristeći se podacima iz studija *EMPHASIS-HF*, *PARADIGM-HF* i *DAPA-HF*, analiziralo se preživljavanje uz cjelokupnu te-

across the three trials.^{127,128} Given the significant interaction of vericiguat effects according to baseline NT-proBNP levels, a *post hoc* analysis showed an association of vericiguat benefit on the primary outcome in patients with NTproBNP levels up to 8000 pg/mL, with greatest benefit in patients with NTproBNP <4000 pg/mL (HR, 0,77, 95% CI, 0,68–0,88).¹²⁹

Vericiguat was evaluated in HFpEF patients in the *VITALITY* trial,¹²⁸ showing no benefit in quality of life and exercise tolerance.¹³⁰ Similarly, in the *CAPACITY* trial, the sGC stimulator praliciguat was well-tolerated but did neither affect the primary efficacy endpoint of pVO₂ nor other predefined outcome parameters.¹³¹

CARDIAC MYOSIN ACTIVATORS AND INHIBITORS

Omecantiv mecarbil (*GALACTIC-HF*, *EXPLOER-HCM*)

Omecantiv mecarbil, a cardiac myosin activator that enhances cardiomyocyte contraction, given twice daily on the basis of plasma levels of the drug, significantly reduced the primary endpoint of HF hospitalisation and CV death in patients with HFrEF and a recent HF event (HR, 0,92; 95% CI, 0,86–0,99; P = 0,03) but had no impact on any of the secondary outcomes (CV death, change in symptom score, first HF hospitalization, and death from any cause).¹³²

A similar compound, *danicamtiv*, increased stroke volume, improved global longitudinal and circumferential strain, decreased LA minimal volume index, and increased LA function index when compared to placebo in a small phase 2a trial in 40 patients with stable HFrEF.¹³³

On the other hand, *mavacamten*, a myosin inhibitor, significantly improved the combined primary endpoint of increase in peak oxygen consumption (pVO₂) and reduction in NYHA class in a phase 3 trial in patients with obstructive hypertrophic cardiomyopathy. Also, outflow tract obstruction and health status were improved.¹³⁴

Other therapies

FERRIC CARBOXYMALTOSE (*AFFIRM-AHF*)

In iron-deficient patients hospitalized for acute HF (*AFFIRM-AHF*)¹³⁵ intravenous ferric carboxymaltose compared to placebo was associated with a trend to reduced total HF hospitalizations and CV death (rate ratio 0,79, 95% CI 0,62–1,01, P = 0,059). In a pre-specified sensitivity analysis considering the impact of the COVID-19 pandemic, a statistically significant difference in favour of ferric carboxymaltose was reported for the primary endpoint was reported, but not in CV death risk.¹³⁶

MICRORNA-132 INHIBITION

In a first clinical trial limited by a small number of HF patients, the antisense oligonucleotide drug directed against miR-132, CDR132L,¹³⁷ was well tolerated and showed first hints for a cardiac functional improvement.¹³⁸

COMPREHENSIVE DISEASE-MODIFYING PHARMACOLOGICAL THERAPIES

Using data from the *EMPHASIS-HF*, *PARADIGM-HF*, and *DAPA-HF* trials lifetime gains in survival have been estimated with comprehensive therapy (SV, β-blocker, MRA, and SGLT-2

meljnu terapiju (SV, beta-blokatore, antagoniste mineralokortikoidnih receptora i SGLT-2 inhibitore) spram grupe RAAS lijekova i beta-blokatora u bolesnika s kroničnim HFrEF-om.^{11,139} Omjer rizika za zajednički cilj (CV smrtnost ili hospitalizacije zbog HF-a) iznosio je 0,38 (95 % CI 0,30 – 0,47). Povoljni su rezultati također bili uočeni za CV smrtnost, hospitalizacije zbog HF-a, kao i za ukupnu smrtnost. Cjelokupna farmakološka terapija može produljiti preživljavanje oko 6,3 godine u bolesnika prosječne dobi 55 godina. Ovakav rezultati podržavaju primjenu kombinirane uporabe SV-a, beta-blokatora, antagonista mineralokortikoidnih receptora i SGLT-2 inhibitora kao novi terapijski standard.

Liječenje intervencijama/uređajima

SEKUNDARNA (ILI FUNKCIONALNA) MITRALNA REGURGITACIJA (STUDIJA COAPT)

Sekundarna (ili funkcionalna) mitralna regurgitacija (SMR) pojavljuje se često u bolesnika s HFrEF-om, a povezana je s progresivnom simptomatologijom i pogoršanjem prognoze. Ako se SMR tretira pristupom „edge-to-edge“, bolesnici s optimalnim rezultatima pri otpustu i pri 12-mjesečnom praćenju pokazuju najbolji ishod.¹⁴⁰

SRČANA RESINKRONIZACIJSKA TERAPIJA (STUDIJA STOP-CRT)

Srčana resinkronizacijska terapija (studija *STOP-CRT*) sastavni je dio liječenja bolesnika s HFrEF-om, posebno uz blok lijeve grane i široki QRS-kompleks. U selekcioniranoj skupini bolesnika s LVEF-om >50% uz CRT i neurohormonalnu blokadu iz studije *STOP-CRT*, proučavane su sigurnost i izvedivost prekidanja neurohormonalne blokade. Incidencija lošijeg remodeliranja LV-a ili kliničkih rezultata bila je mala nakon prekida beta-blokade/RAAS inhibicije. No, komorbiditeti potiču nastavak neurohormonalne blokade u mnogih bolesnika.¹⁴¹

U bolesnika s HFrEF-om, ako nisu bili pogodni za CRT, barorefleksna aktivacijska terapija (BAT) može biti korisna kao dodatak optimalnoj primjeni lijekova. U istraživanju *BeAT-HF* BAT je bila sigurna terapija i znatno je poboljšala učestalost simptoma, kvalitetu života, podnošenje napora, kao i vrijednost NT-proBNP.¹⁴² Na temelju navedenih podataka, BAT je odobren u SAD-u, dok će praćenje rezultata *BeAT-HF* studije pokazati učinak na značajne ishode.

Specifična liječenja

TELEMEDICINA I DRUGE VRSTE PRAĆENJA NA DALJINU

Uloga telemedicine i praćenja na daljinu u liječenju bolesnika s HF-om još je uvijek proturječna. Opservacijska studija iz triju europskih zemalja, pokazuje da je liječenje HF-a vođeno monitoriranjem plućnoga arterijskoga tlaka (PAP) izvedivo i sigurno i povezano s boljim hemodinamskim i kliničkim ishodima.¹⁴³ Osim toga, preliminarni rezultati testiranja neinvazivnoga daljinskoga fiziološkog monitoriranja s pomoću nosivog senzora imaju obećavajuće rezultate u ranom otkrivanju potencijalne rehospitalizacije zbog HF-a.¹⁴⁴ No različiti modeli monitoriranja na daljinu nisu pokazali pozitivne učinke u poboljšanju liječenja i kvalitete života¹⁴⁵ ili pak kliničkih ishoda.¹⁴⁶ Monitoriranje bolesnika na daljinu s implantiranim

inhibitor) vs. RAAS and β -blockers in patients with chronic HFrEF.^{11,139} The HR for the composite endpoint of CV death or hospitalisation for HF was 0.38 (95% CI 0.30–0.47). Favourable results were also calculated for CV death alone, hospitalization for HF alone, and all-cause mortality. Comprehensive therapy could prolong overall survival 6.3 years in average in a 55-year-old patient. These results support the combination use of SV, β -blockers, mineralocorticoid receptor antagonists, and SGLT-2 inhibitors as a new therapeutic standard.

Device/interventional therapies

SECONDARY (OR FUNCTIONAL) MITRAL REGURGITATION (COAPT)

Secondary (or functional) mitral regurgitation (SMR) occurs frequently in HFrEF and is associated with progressive symptoms and worse prognosis. If SMR is treated by edge-to-edge repair, patients with optimal result at discharge and 12-month follow-up displayed best outcomes.¹⁴⁰

CARDIAC RESYNCHRONIZATION THERAPY (STOP-CRT)

Cardiac resynchronization therapy (STOP-CRT) is an integral part of treatment in patients with HFrEF, especially with left bundle branch block and wide QRS. In a selected cohort of patients with LVEF >50% during CRT and neurohormonal blockade, the STOP-CRT study investigated the feasibility and safety of neurohormonal blocker withdrawal. The incidence of adverse LV remodelling or clinical outcomes was low after discontinuation of betablockade/RAAS inhibition. However, comorbidities prompted the continuation of neurohormonal blockers in many patients.¹⁴¹

In patients with HFrEF who are ineligible for CRT, baroreflex activation therapy (BAT) may be useful in addition to optimal drug therapy. In the *BeAT-HF* study, BAT was safe and significantly improved symptoms, quality of life, exercise capacity, and NT-proBNP.¹⁴² On the basis of these data, BAT was approved in the USA, while ongoing follow-up in the *BeAT-HF* study will assess effects on hard outcomes.

Specific management issues

TELEMEDICINE AND REMOTE MONITORING

The role of telemedicine and remote monitoring in the management of HF patients is still controversial. An observational study in three European countries showed that pulmonary artery pressure-guided HF management is feasible and safe and associated with better outcomes haemodynamic and clinical outcomes.¹⁴³ Also, preliminary results testing non-invasive remote physiological monitoring from a wearable sensor showed promising results in the early detection of impending HF rehospitalisation.¹⁴⁴ However, different modes of remote monitoring failed to show a benefit in improving treatment, quality of life,¹⁴⁵ or clinical outcomes.¹⁴⁶ Moreover, remote monitoring with a cardiac implanted electronic device increased clinical activity for patients with HF and AF, with no associated reduction in mortality, and conversely, greater risk of CV hospitalisation amongst patients with persistent/permanent AF.¹⁴⁷ In the COVID-19 era, remote monitoring is a useful tool for managing HF patients.¹⁴⁸

elektroničkim uređajem srca, povećava kliničku aktivnost bolesnika s HF-om i fibrilacijom atriya, no nije povezano sa smanjenjem smrtnosti, a povezano je s većim rizikom od CV hospitalizacija kod bolesnika sa perzistentnom/permanentnom fibrilacijom atriya.¹⁴⁷ U eri COVID-a 19 monitoriranje na daljinu može biti korisno u liječenju bolesnika s HF-om.¹⁴⁸

BRIGA O SEBI I PALIJATIVNA NJEGA

Briga o sebi esencijalna je u liječenju kroničnog HF-a. Praktični savjeti za ključne aktivnosti i prioritete opisani su u članku Europskog društva za zatajivanje srca (HFA).¹⁴⁹ Pri kraju kontinuuma bolesnika s HF-om, palijativnu bi brigu trebalo uvesti što prije, usredotočujući se na liječenje simptoma,¹⁵⁰ neovisno o prognozi, što se za sada u Europi malo primjenjuje.¹⁵¹ Provođenje palijativne njege smanjuje broj hospitalizacija, no učinak na preživljenje nije toliko jasan.¹⁵²

SELF-CARE AND PALLIATIVE CARE

Self-care is essential in the management of chronic HF. Practical advice for key activities and priorities for self-care is given in an HFA manuscript.¹⁴⁹ At the end of the HF pathway, palliative care should be introduced early, focusing on symptom management,¹⁵⁰ regardless of prognosis, but actually only a minority in Europe receive it.¹⁵¹ Providing palliative care substantially reduces hospitalizations, with no clear adverse effect on survival.¹⁵²

Funding

There was no specific funding for the development of this manuscript. J. Bauersachs is supported by the Deutsche Forschungsgemeinschaft, KFO 311, "Advanced cardiac and pulmonary failure: mechanical unloading and repair".

Disclosures: Dr. Bueno reports grants from Instituto de Salud Carlos III, grants from Sociedad Española de Cardiología, grants from Astra-Zeneca, grants and personal fees from Bayer, grants and personal fees from BMS, grants and personal fees from Novartis.

Dr. Moura reports personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Servier, personal fees from Novartis, personal fees from Merck Serono, personal fees from Elly -Lilly, personal fees from Boehringer-Ingelheim.

Dr. Bauersachs reports personal fees from Abbott, grants and personal fees from Abiomed, personal fees from Astra Zeneca, personal fees from Bayer, personal fees from BMS, personal fees from Boehringer Ingelheim, grants and personal fees from CvRX, personal fees from Daiichi Sankyo, personal fees from Medtronic, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Servier, grants and personal fees from Vifor, grants from Zoll, personal fees from Cardior. In addition, Dr. Bauersachs is Board Member of Cardior and has a patent PCT/EP2007/008772 with royalties paid, and a patent PCT/EP2009/051986 with royalties paid both on microRNA (miRNA) and downstream targets for diagnostic and therapeutic.

Dr Lancellotti has no relevant disclosures.

LITERATURE

- Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail.* 2020;22:1342-56. <https://doi.org/10.1002/ehf.1858>
- Sulo G, Iglund J, Øverland S, Egeland GM, Roth GA, Vollset SE, et al. Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project. *Eur J Heart Fail.* 2020;22:241-8. <https://doi.org/10.1002/ehf.1609>
- Uijl A, Koudstaal S, Direk K, Denaxas S, Groenwold RHH, Banerjee A, et al. Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records. *Eur J Heart Fail.* 2019;21:197-206. <https://doi.org/10.1002/ehf.1350>
- White-Williams C, Rossi LP, Bittner VA, Driscoll A, Durant RW, Granger BB, et al; On behalf of the American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology; and Council on Epidemiology and Prevention. Addressing social determinants of health in the care of patients with heart failure: a scientific statement from the American Heart Association. *Circulation.* 2020;141:e841-63. <https://doi.org/10.1161/CIR.0000000000000767>
- Velagaleti RS, Larson MG, Enserro D, Song RJ, Vasan RS. Clinical course after a first episode of heart failure: insights from the Framingham Heart Study. *Eur J Heart Fail.* 2020;22:1768-76. <https://doi.org/10.1002/ehf.1918>
- Tayal B, Frøelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, et al. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study. *Eur Heart J.* 2019;40:3641-8. <https://doi.org/10.1093/eurheartj/ehz584>
- Barra S, Providência R, Narayanan K, Boveda S, Duehmke R, Garcia R, et al. Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. *Eur Heart J.* 2020;41:1976-86. <https://doi.org/10.1093/eurheartj/ehz773>
- Motiejūnaitė J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi D-J, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. *Eur Heart J.* 2020;41:1357-64. <https://doi.org/10.1093/eurheartj/ehaa071>
- Parizo JT, Kohsaka S, Sandhu AT, Patel J, Heidenreich PA. Trends in readmission and mortality rates following heart failure hospitalization in the Veterans Affairs Health Care System from 2007 to 2017. *JAMA Cardiol.* 2020;5:1042-7. <https://doi.org/10.1001/jamacardio.2020.2028>
- Butt JH, Fosbø EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. *Eur J Heart Fail.* 2020;22:1777-85. <https://doi.org/10.1002/ehf.1800>
- Jhund PS. The recurring problem of heart failure hospitalisations. *Eur J Heart Fail.* 2020;22:249-50. <https://doi.org/10.1002/ehf.1721>

12. Ćelutkienė J, Lainscak M, Anderson L, Gayat E, Grapsa J, Harjola V-P, et al. Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:181-95. <https://doi.org/10.1002/ejhf.1678>
13. Paterson DJ, Wells G, Erthal F, Mielniczuk L, O'Meara E, White J, et al. OUTSMART HF: a randomized controlled trial of routine versus selective cardiac magnetic resonance for patients with nonischemic heart failure (IMAGE-HF 1B). *Circulation.* 2020;141:818-27. <https://doi.org/10.1161/CIRCULATIONAHA.119.043964>
14. Quarta G, Gori M, Iorio A, D'Elia E, Moon JC, Iacovoni A, et al. Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. *Eur J Heart Fail.* 2020;22:1065-75. <https://doi.org/10.1002/ejhf.1961>
15. Pezel T, Viallon M, Croisille P, Sebbag L, Bochaton T, Garot J, et al. Imaging interstitial fibrosis, left ventricular remodeling, and function in stage A and B heart failure. *JACC Cardiovasc Imaging.* 2020;***: <https://doi.org/10.1016/j.jcmg.2020.05.036> [cited 2020 December 24]
16. Emrich T, Hahn F, Fleischmann D, Halfmann MC, Düber C, Varga-Szemes A, et al. T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction. *ESC Heart Fail.* 2020;7:2544-52. <https://doi.org/10.1002/ehf2.12830>
17. Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. *JACC Cardiovasc Imaging.* 2020;13:283-96. <https://doi.org/10.1016/j.jcmg.2019.02.031>
18. Putko BN, Savu A, Kaul P, Ezekowitz J, Dyck JR, Anderson TJ, et al. Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. *Eur Heart J Cardiovasc Imaging.* 2021;***: [10.1093/ehjci/jeaa041](https://doi.org/10.1093/ehjci/jeaa041) [cited 2020 December 24]
19. Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week. *J Am Coll Cardiol.* 2020;76:1102-11. <https://doi.org/10.1016/j.jacc.2020.06.069>
20. Lin T-T, Wang Y-C, Juang J-M, Hwang J-J, Wu C-K. Application of the newest European Association of Cardiovascular Imaging Recommendation regarding the long-term prognostic relevance of left ventricular diastolic function in heart failure with preserved ejection fraction. *Eur Radiol.* 2020;30:630-9. <https://doi.org/10.1007/s00330-019-06261-1>
21. Romano G, Magro S, Agnese V, Mina C, Di Gesaro G, Falletta C, et al. Echocardiography to estimate high filling pressure in patients with heart failure and reduced ejection fraction. *ESC Heart Fail.* 2020;7:2268-77. <https://doi.org/10.1002/ehf2.12748>
22. Tanacii R, Hashemi D, Neye M, Motzkus LA, Blum M, Tahirovic E, et al. Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction. *ESC Heart Fail.* 2020;7:3240-5. <https://doi.org/10.1002/ehf2.12826>
23. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. *JACC Heart Fail.* 2020;8:640-53. <https://doi.org/10.1016/j.jchf.2020.03.013>
24. Yoshihisa A, Sato Y, Kanno Y, Takiguchi M, Yokokawa T, Abe S, et al. Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. *Open Heart.* 2020;7:e001112. <https://doi.org/10.1136/openhrt-2019-001112>
25. Wang C-L, Chan Y-H, Wu VC-C, Lee H-F, Hsiao F-C, Chu P-H. Incremental prognostic value of global myocardial work over ejection fraction and global longitudinal strain in patients with heart failure and reduced ejection fraction. *Eur Heart J Cardiovasc Imaging.* 2021;***: [10.1093/ehjci/jeaa162](https://doi.org/10.1093/ehjci/jeaa162)
26. Mazzetti S, Scifo C, Abete R, Margonato D, Chioffi M, Rossi J, et al. Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan. *ESC Heart Fail.* 2020;7:964-72. <https://doi.org/10.1002/ehf2.12656>
27. Zhou W, Brown JM, Bajaj NS, Chandra A, Divakaran S, Weber B, et al. Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. *Eur Heart J.* 2020;41:2366-75. <https://doi.org/10.1093/eurheartj/ehaa191>
28. Escaned J, Lerman LO. Coronary microcirculation and hypertensive heart failure. *Eur Heart J.* 2020;41:2376-8. <https://doi.org/10.1093/eurheartj/ehaa377>
29. Seo M, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, et al. Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute. *Eur Heart J Cardiovasc Imaging.* 2021;***: <https://doi.org/10.1093/ehjci/jeaa025> [cited 2020 December 24]
30. Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. *J Am Coll Cardiol.* 2020;76:503-14. <https://doi.org/10.1016/j.jacc.2020.05.072>
31. Aimo A, Januzzi JL, Vergaro G, Richards AM, Lam CSP, Latini R, et al. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. *Eur J Heart Fail.* 2020;22:2078-88. <https://doi.org/10.1002/ejhf.1701>
32. Ferreira JP, Ouwerkerk W, Santema BT, van Veldhuisen DJ, Lang CC, Ng LL, et al. Differences in biomarkers and molecular pathways according to age for patients with HFrEF. *Cardiovasc Res.* 2020;***: <https://doi.org/10.1093/cvr/cvaa279>
33. Möckel M, Boer RA, Slagman AC, Haehling S, Schou M, Vollert JO, et al. Improve management of acute heart failure with ProcaAlCITonin in Europe: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18. *Eur J Heart Fail.* 2020;22:267-75. <https://doi.org/10.1002/ejhf.1667>
34. Bayes-Genis A, Liu PP, Lanfear DE, de Boer RA, González A, Thum T, et al. Omics phenotyping in heart failure: the next frontier. *Eur Heart J.* 2020;41:3477-84. <https://doi.org/10.1093/eurheartj/ehaa270>
35. McGranaghan P, Düngen H-D, Saxena A, Rubens M, Salami J, Radenkovic J, et al. Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients. *ESC Heart Fail.* 2020;7:3029-39. <https://doi.org/10.1002/ehf2.12928>
36. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181:271-280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>
37. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. *Eur Heart J.* 2020;41:1821-9. <https://doi.org/10.1093/eurheartj/ehaa388>
38. Sama IE, Ravera A, Santema BT, van Goo H, ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J.* 2020;41:1810-7. <https://doi.org/10.1093/eurheartj/ehaa373>
39. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. *Eur J Heart Fail.* 2020;22:957-66. <https://doi.org/10.1002/ejhf.1871>
40. de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. *Lancet.* 2020;395:1705-14. [https://doi.org/10.1016/S0140-6736\(20\)31030-8](https://doi.org/10.1016/S0140-6736(20)31030-8)
41. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. *Eur J Heart Fail.* 2020;22:967-74. <https://doi.org/10.1002/ejhf.1924>
42. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Ilturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. *N Engl J Med.* 2020;382:2441-8. <https://doi.org/10.1056/NEJMoa2008975>
43. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. *N Engl J Med.* 2020;382:2431-40. <https://doi.org/10.1056/NEJMoa2006923>
44. Rey JR, Caro-Codón J, Rosillo SO, Iniesta ÁM, Castrejón-Castrejón S, Marco-Clement I, et al. Heart failure in Covid-19 patients: prevalence, incidence and prognostic implications. *Eur J Heart Fail.* 2020;***: <https://doi.org/10.1002/ejhf.1990>

45. Bromage DI, Cannatà A, Rind IA, Gregorio C, Piper S, Shah AM, et al. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. *Eur J Heart Fail.* 2020;22:978-84. <https://doi.org/10.1002/ejhf.1925>
46. Andersson C, Gerds T, Fosbøl E, Phelps M, Andersen J, Lamberts M, et al. Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. *Circ Heart Fail.* 2020;13:e007274. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007274>
47. Cannatà A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, et al. Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. *Eur J Heart Fail.* 2020;***. <https://doi.org/10.1002/ejhf.1986> [cited 2020 December 24]
48. Zhang Y, Coats AJS, Zheng Z, Adamo M, Ambrosio G, Anker SD, et al. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:941-56. <https://doi.org/10.1002/ejhf.1915>
49. D'Amario D, Restivo A, Canonico F, Rodolico D, Mattia G, Francesco B, et al. Experience of remote cardiac care during the COVID-19 pandemic: the V-LAPTM device in advanced heart failure. *Eur J Heart Fail.* 2020;22:1050-2. <https://doi.org/10.1002/ejhf.1900>
50. Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, et al. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J.* 2020;41:2109-17. <https://doi.org/10.1093/eurheartj/ehaa461>
51. Truby LK, O'Connor C, Fiuza T, Stebbins A, Coles A, Patel CB, et al. Sex differences in quality of life and clinical outcomes in patients with advanced heart failure: insights from the PAL-HF trial. *Circ Heart Fail.* 2020;13:e006134. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006134>
52. Lainščak M, Milinković I, Polovina M, Crespo-Leiro MG, Lund LH, Anker SD, et al.; on behalf of the European Society of Cardiology Heart Failure Long-Term Registry Investigators Group. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. *Eur J Heart Fail.* 2020;22:92-102. <https://doi.org/10.1002/ejhf.1645>
53. Rossello X, Ferreira JP, Pocock SJ, McMurray JJV, Solomon SD, Lam CSP, et al. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. *Eur J Heart Fail.* 2020;22:834-44. <https://doi.org/10.1002/ejhf.1740>
54. Dewan P, Jackson A, Lam CSP, Pfeffer MA, Zannad F, Pitt B, et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. *Eur J Heart Fail.* 2020;22:898-901. <https://doi.org/10.1002/ejhf.1776>
55. Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, et al. Representation of women authors in international heart failure guidelines and contemporary clinical trials. *Circ Heart Fail.* 2020;13:e006605. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006605>
56. Pandey A, Vaduganathan M, Arora S, Qamar A, Mentz RJ, Shah SJ, et al. Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance. *Circulation.* 2020;142:230-43. <https://doi.org/10.1161/CIRCULATIONAHA.120.047019>
57. Khan MS, Samman Tahhan A, Vaduganathan M, Greene SJ, Alrohaibani A, Anker SD, et al. Trends in prevalence of comorbidities in heart failure clinical trials. *Eur J Heart Fail.* 2020;22:1032-42. <https://doi.org/10.1002/ejhf.1818>
58. Bhatt AS, Ambrosy AP, Dunning A, DeVore AD, Butler J, Reed S, et al. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. *Eur J Heart Fail.* 2020;22:1022-31. <https://doi.org/10.1002/ejhf.1795>
59. Aimo A, Barison A, Castiglione V, Emdin M. The unbearable underreporting of comorbidities in heart failure clinical trials. *Eur J Heart Fail.* 2020;22:1043-4. <https://doi.org/10.1002/ejhf.1846>
60. Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Böhm M, et al. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. *Eur J Heart Fail.* 2020;22:528-38. <https://doi.org/10.1002/ejhf.1682>
61. Al-Khatib SM, Benjamin EJ, Albert CM, Alonso A, Chauhan C, Chen P-S, et al. Advancing research on the complex interrelations between atrial fibrillation and heart failure: a report from a US National Heart, Lung, and Blood Institute Virtual Workshop. *Circulation.* 2020;141:1915-26. <https://doi.org/10.1161/CIRCULATIONAHA.119.045204>
62. Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. *Eur J Heart Fail.* 2020;22:214-27. <https://doi.org/10.1002/ejhf.1646>
63. Bauersachs J, Veltmann C. Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon. *Eur J Heart Fail.* 2020;22:539-42. <https://doi.org/10.1002/ejhf.1733>
64. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:584-603. <https://doi.org/10.1002/ejhf.1697>
65. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. *JACC Heart Fail.* 2020;8:157-68. <https://doi.org/10.1016/j.jchf.2019.09.012>
66. Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, et al.; the Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. *Eur J Heart Fail.* 2020;22:1684-93. <https://doi.org/10.1002/ejhf.1743>
67. Harjola V-P, Parissis J, Bauersachs J, Brunner-La Rocca H-P, Bueno H, Čelutkienė J, et al. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:1298-314. <https://doi.org/10.1002/ejhf.1831>
68. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, et al. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care.* 2020;9:348-57. <https://doi.org/10.1177/2048872619894255>
69. Aissaoui N, Puymirat E, Delmas C, Ortuno S, Durand E, Bataille V, et al. Trends in cardiogenic shock complicating acute myocardial infarction. *Eur J Heart Fail.* 2020;22:664-72. <https://doi.org/10.1002/ejhf.1750>
70. Hanson ID, Tagami T, Mando R, Kara Balla A, Dixon SR, Timmis S, et al.; National Cardiogenic Shock Investigators. SCAI shock classification in acute myocardial infarction: insights from the National Cardiogenic Shock Initiative. *Catheter Cardiovasc Interv.* 2020;96:1137-42. <https://doi.org/10.1002/ccd.29139>
71. Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care.* 2020;9:183-97. <https://doi.org/10.1177/2048872619894254>
72. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock—a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:1315-41. <https://doi.org/10.1002/ejhf.1922>
73. Karason K, Lund LH, Dalén M, Björklund E, Grinnemo K, Braun O, et al. the SweVAD Investigators. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. *Eur J Heart Fail.* 2020;22:739-50. <https://doi.org/10.1002/ejhf.1773>
74. Phan D, Duan L, Ng A, Shen AY-J, Lee M-S. Characteristics and outcomes of pregnant women with cardiomyopathy stratified by etiologies: a population-based study. *Int J Cardiol.* 2020;305:87-91. <https://doi.org/10.1016/j.ijcard.2019.12.027>
75. Bauersachs J, König T, Meer P, Petrie MC, Hilfiger-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail.* 2019;21:827-43. <https://doi.org/10.1002/ejhf.1493>

76. Sliwa K, Bauersachs J, Coats AJS. The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy—what has been achieved in 10 years. *Eur J Heart Fail.* 2020;22:1060-4. <https://doi.org/10.1002/ehf.1912>
77. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. *Eur Heart J.* 2020;41:3787-97. <https://doi.org/10.1093/eurheartj/ehaa455>
78. Davis MB, Arany Z, McNamara DM, Golland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol.* 2020;75:207-21. <https://doi.org/10.1016/j.jacc.2019.11.014>
79. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With recovered left ventricular ejection fraction: JACC Scientific Expert Panel. *J Am Coll Cardiol.* 2020;76:719-34. <https://doi.org/10.1016/j.jacc.2020.05.075>
80. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol.* 2020;31:171-90. <https://doi.org/10.1016/j.annonc.2019.10.023>
81. Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiography in cardio-oncology. *Echocardiography.* 2020;37:149-58. <https://doi.org/10.1111/echo.14800>
82. Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, et al. Magnetic resonance imaging to detect cardiovascular effects of cancer therapy. *JACC CardioOncology.* 2020;2:270-92. <https://doi.org/10.1016/j.jacc.2020.04.011>
83. Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. *Eur Heart J.* 2020;41:1733-43. <https://doi.org/10.1093/eurheartj/ehaa051>
84. Border WL, Sachdeva R, Stratton KL, Armenian SH, Bhat A, Cox DE, et al. Longitudinal changes in echocardiographic parameters of cardiac function in pediatric cancer survivors. *JACC CardioOncology.* 2020;2:26-37. <https://doi.org/10.1016/j.jacc.2020.02.016>
85. López-Sendón J, Álvarez-Ortega C, Zamora Añón P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. *Eur Heart J.* 2020;41:1720-9. <https://doi.org/10.1093/eurheartj/ehaa006>
86. Reddy YNV, Obokata M, Wiley B, Koepf KE, Jorgenson CC, Egbe A, et al. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. *Eur Heart J.* 2019;40:3721-30. <https://doi.org/10.1093/eurheartj/ehz713>
87. Obokata M, Kane GC, Reddy YNV, Melenovsky V, Olson TP, Jarolim P, et al. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. *Eur Heart J.* 2019;40:3707-17. <https://doi.org/10.1093/eurheartj/ehz626>
88. Padang R, Chandrashekar N, Indrabinduwar M, Scott CG, Luis SA, Chandrasekaran K, et al. Aetiology and outcomes of severe right ventricular dysfunction. *Eur Heart J.* 2020;41:1273-82. <https://doi.org/10.1093/eurheartj/ehaa037>
89. Patel D, Trulock K, Kumar A, Kiehl E, Toro S, Moennich LA, et al. Baseline right ventricular dysfunction predicts worse outcomes in patients undergoing cardiac resynchronization therapy implantation. *J Card Fail.* 2020;26:227-32. <https://doi.org/10.1016/j.cardfail.2019.12.004>
90. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis. *JACC Heart Fail.* 2020;8:844-55. <https://doi.org/10.1016/j.jchf.2020.06.015>
91. Lee S, Oh J, Kim H, Ha J, Chun K-h, Lee C-J, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. *ESC Heart Fail.* 2020;7:1125-9. <https://doi.org/10.1002/ehf2.12659>
92. Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, et al. Sacubitril/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the IIFE trial. *JACC Heart Fail.* 2020;8:789-99. <https://doi.org/10.1016/j.jchf.2020.05.005>
93. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. *Circulation.* 2020;141:338-51. <https://doi.org/10.1161/CIRCULATIONAHA.119.044491>
94. Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. *J Am Coll Cardiol.* 2020;75:245-54. <https://doi.org/10.1016/j.jacc.2019.11.003>
95. Selvaraj S, Claggett BL, Böhm M, Anker SD, Vaduganathan M, Zannad F, et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. *J Am Coll Cardiol.* 2020;75:1644-56. <https://doi.org/10.1016/j.jacc.2020.02.009>
96. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. *Circulation.* 2020;142:1236-45. <https://doi.org/10.1161/CIRCULATIONAHA.120.047643>
97. Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, et al. Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. *Eur J Heart Fail.* 2020;22:2093-101. <https://doi.org/10.1002/ehf.1984>
98. Kuno T, Ueyama H, Fujisaki T, Briasoulis A, Takagi H, Briasoulis A. Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction. *Am J Cardiol.* 2020;125:1187-93. <https://doi.org/10.1016/j.amjcard.2020.01.009>
99. Vaduganathan M, Jhund PS, Claggett BL, Packer M, Widimský J, Seferovic P, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. *Eur Heart J.* 2020;41:2356-62. <https://doi.org/10.1093/eurheartj/ehaa184>
100. Böhm M, Bewarwarder Y, Kindermann I. Ejection fraction in heart failure revisited—where does the evidence start? *Eur Heart J.* 2020;41:2363-5. <https://doi.org/10.1093/eurheartj/ehaa281>
101. Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, et al. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2020;22:1495-503. <https://doi.org/10.1002/ehf.1954>
102. Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. *Eur J Heart Fail.* 2020;22:196-213. <https://doi.org/10.1002/ehf.1673>
103. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med.* 2020;383:1425-35. <https://doi.org/10.1056/NEJMoa2004967>
104. Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al. On behalf of the VERTIS CV Investigators. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. *Circulation.* 2020;142:2205-15. <https://doi.org/10.1161/CIRCULATIONAHA.120.050255>
105. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019;381:1995-2008. <https://doi.org/10.1056/NEJMoa1911303>
106. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al; on behalf of the DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). *Eur J Heart Fail.* 2019;21:665-75. <https://doi.org/10.1002/ehf.1432>
107. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. *JAMA.* 2020;323:1353-68. <https://doi.org/10.1001/jama.2020.1906>
108. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. *Eur Heart J.* 2020;41:2379-92. <https://doi.org/10.1093/eurheartj/ehaa183>

109. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. *Circulation*. 2020;141:100-11. <https://doi.org/10.1161/CIRCULATIONAHA.119.044133>
110. Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). *Eur Heart J*. 2020;41:3402-18. <https://doi.org/10.1093/eurheartj/ehaa496>
111. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. *Circulation*. 2021;:;. <https://doi.org/10.1161/CIRCULATIONAHA.120.050391> [cited 2020 December 24]
112. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. *Circulation*. 2020;141:90-9. <https://doi.org/10.1161/CIRCULATIONAHA.119.044138>
113. McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, Böhm M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. *Eur J Heart Fail*. 2020;22:2147-56. <https://doi.org/10.1002/ehfj.1978>
114. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertov GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383:1436-46. <https://doi.org/10.1056/NEJMoa2024816>
115. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*. 2020;383:1413-24. <https://doi.org/10.1056/NEJMoa2022190>
116. Packer M, Anker SD, Butler J, Filippatos GS, Ferreira JP, Pocock S, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Circulation*. 2021;:;. <https://doi.org/10.1161/CIRCULATIONAHA.120.051783> [cited 2020 December 24]
117. Packer M. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J*. 2021. Forthcoming <https://doi.org/10.1093/eurheartj/ehz553>
118. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status—results from the EMPEROR-Reduced trial. *Circulation*. 2021;:;. <https://doi.org/10.1161/CIRCULATIONAHA.120.051824>
119. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet*. 2020;396:819-29. [https://doi.org/10.1016/S0140-6736\(20\)31824-9](https://doi.org/10.1016/S0140-6736(20)31824-9)
120. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). *Circulation*. 2021;:;. <https://doi.org/10.1161/CIRCULATIONAHA.120.052186> [cited 2020 December 24]
121. Santos-Gallego CG, Vargas-Delgado AP, Requena JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized trial of empagliflozin in non-diabetic patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol*. 2021;:;. <https://doi.org/10.1016/j.jacc.2020.11.008>
122. Butler J, Zannad F, Filippatos G, Anker SD, Packer M. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. *Eur Heart J*. 2020;41:3398-401. <https://doi.org/10.1093/eurheartj/ehaa731>
123. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med*. 2021;:;. <https://doi.org/10.1056/NEJMoa2030183> [cited 2020 December 24]
124. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *N Engl J Med*. 2021;:;. <https://doi.org/10.1056/NEJMoa2030186> [cited 2020 December 24]
125. Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, et al.; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. *Eur J Heart Fail*. 2019;21:1596-604. <https://doi.org/10.1002/ehfj.1664>
126. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2020;382:1883-93. <https://doi.org/10.1056/NEJMoa1915928>
127. Butler J, Anstrom KJ, Armstrong PW; For the VICTORIA Study Group. Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. *Circulation*. 2020;142:717-9. <https://doi.org/10.1161/CIRCULATIONAHA.120.047086>
128. Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, et al. Rationale and design of the VITALITY-HFpEF trial. *Circ Heart Fail*. 2019;12:e005998. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.005998>
129. Ezekowitz JA, O'Connor CM, Troughton RW, Alemyahu WG, Westerhout CM, Voors AA, et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. *JACC Heart Fail*. 2020;8:931-9. <https://doi.org/10.1016/j.jchf.2020.08.008>
130. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, et al.; VITALITY-HFpEF Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. *JAMA*. 2020;324:1512-21. [Oct] <https://doi.org/10.1001/jama.2020.15922>
131. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, et al. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliquat over 12 weeks in patients with heart failure with preserved ejection fraction. *Am Heart J*. 2020;222:183-90. <https://doi.org/10.1016/j.ahj.2020.01.009>
132. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. *N Engl J Med*. 2021;:;. <https://doi.org/10.1056/NEJMoa2025797> [cited 2020 December 24]
133. Voors AA, Tamby J-F, Cleland JG, Koren M, Forgosh LB, Gupta D, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. *Eur J Heart Fail*. 2020;22:1649-58. <https://doi.org/10.1002/ehfj.1933>
134. Olivetto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2020;396:759-69. [https://doi.org/10.1016/S0140-6736\(20\)31792-X](https://doi.org/10.1016/S0140-6736(20)31792-X)
135. Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozd J, Fabien V, et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. *Eur J Heart Fail*. 2019;21:1651-8. <https://doi.org/10.1002/ehfj.1710>
136. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozd J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet*. 2020;:;. [https://doi.org/10.1016/S0140-6736\(20\)32339-4](https://doi.org/10.1016/S0140-6736(20)32339-4) [cited 2020 December 24]
137. Batkai S, Genschel C, Viereck J, Rump S, Bär C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. *Eur Heart J*. 2021;:;. <https://doi.org/10.1093/eurheartj/ehaa791> [cited 2020 December 24]
138. Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetsch J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. *Eur Heart J*. 2021;:;. <https://doi.org/10.1093/eurheartj/ehaa898> [cited 2020 December 24]
139. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet*. 2020;396:121-8. [https://doi.org/10.1016/S0140-6736\(20\)30748-0](https://doi.org/10.1016/S0140-6736(20)30748-0)

140. Reichart D, Kalbacher D, Rübsamen N, Tigges E, Thomas C, Schirmer J, et al. The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation. *Eur J Heart Fail.* 2020;22:1840-8. <https://doi.org/10.1002/ejhf.1774>
141. Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, et al. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. *J Am Coll Cardiol.* 2020;75:1426-38. <https://doi.org/10.1016/j.jacc.2020.01.040>
142. Zile MR, Lindenfeld JAnn, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. *J Am Coll Cardiol.* 2020;76:1-13. <https://doi.org/10.1016/j.jacc.2020.05.015>
143. Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett M-E, et al; for the MEMS-HF Investigators. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail.* 2020;22:1891-901. [Jun] <https://doi.org/10.1002/ejhf.1943>
144. Stehlik J, Schmalfluss C, Bozkurt B, Nativi-Nicolau J, Wohlfahrt P, Wegerich S, et al. Continuous wearable monitoring analytics predict heart failure hospitalization: the LINK-HF multicenter study. *Circ Heart Fail.* 2020;13:e006513. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006513>
145. Rahimi K, Nazarzadeh M, Pinho-Gomes A-C, Woodward M, Salimi-Khorshidi G, Ohkuma T, et al.; SUPPORT-HF2 Study Group. Home monitoring with technology-supported management in chronic heart failure: a randomised trial. *Heart.* 2020 Oct;106(20):1573-1578. <https://doi.org/10.1136/heartjnl-2020-316773>
146. Galinier M, Roubille F, Berdague P, Briere G, Cantie P, Dary P, et al.; on behalf of the OSICAT Investigators. Telemonitoring versus standard care in heart failure: a randomised multicentre trial. *Eur J Heart Fail.* 2020;22:985-94. <https://doi.org/10.1002/ejhf.1906>
147. Zakeri R, Morgan JM, Phillips P, Kitt S, Ng GA, McComb JM, et al. REM-HF Investigators. Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial. *Eur J Heart Fail.* 2020;22:543-53. <https://doi.org/10.1002/ejhf.1709>
148. Abraham WT, Fiuzat M, Psofka MA, O'Connor CM. Heart failure collaborative statement on remote monitoring and social distancing in the landscape of COVID-19. *JACC Heart Fail.* 2020;8:692-4. <https://doi.org/10.1016/j.jchf.2020.06.006>
149. Jaarsma T, Hill L, Bayes-Genis A, Brunner La Rocca HP, Castiello T, Celutkienė J, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2021;***: <https://doi.org/10.1002/ejhf.2008> [cited 2020 December 24]
150. Hill L, Geller TP, Baruah R, Beattie JM, Boyne J, De Stoutz N, et al. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. *Eur J Heart Fail.* 2020;***: <https://doi.org/10.1002/ejhf.1994>
151. Sobanski PZ, Alt-Epping B, Currow DC, Goodlin SJ, Grodzicki T, Hogg K, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. *Cardiovasc Res.* 2020;116:12-27. <https://doi.org/10.1093/cvr/cvz200>
152. Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. *Eur J Heart Fail.* 2020;***: <https://doi.org/10.1002/ejhf.1783> [cited 2020 December 24]